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Liver failure and cirrhosis remain a significant cause of mortality and 
morbidity worldwide. Despite advances in liver transplantation, the scarcity of 
donor organs puts pressure on the need to explore alternative treatment options 
for patients with liver failure and awaiting transplantation. One such focus has 
been to derive ex vivo hepatocytes from stem cells for the purpose of cellular 
transplantation, to correct liver insufficiency by replacing healthy functional 
hepatocytes into the liver.  
Human amniotic epithelial cells (hAECs) have been touted as an ideal 
stem cell candidate for hepatocyte derivation, being ethically neutral, 
immunologically naïve, plentiful in origin and retaining plasticity in its fetal 
stage. Owing to their expression of HLA-G surface antigen that interacts with 
various immune cells, hAECs also have immunosuppressive and anti-
inflammatory properties.  
We thus aimed to study the potential of these cells and their 
therapeutic potential for treatment of clinical liver cirrhosis. In this thesis, we 
described the successful isolation, expansion and in vitro differentiation of 
these cells into functional hepatocyte-like cells. To establish proof of principle 
of their in vivo therapeutic efficacy, we transplanted these cells into a rodent 
model of liver cirrhosis and determined if these cells were able to engraft, 
escape rejection, reverse cirrhosis and attenuate liver insufficiency. In this 
respect, we compared the relative efficacy of three lineages of hAECs at 
different stages of hepatocyte differentiation to determine their in vitro and in 
vivo therapeutic potential.  
 xii 
1. hAEC-raw - freshly dissociated cells  
2. hAEC-epi- cultured cells in maintenance media  
3. hAEC-hep- hepatic differentiated cells 
In vitro hAECs were characterised by hepatic morphology, genetic 
profile, immunophenotype and function. After in vitro differentiation, hAEC-
hep cells exhibited polygonal morphology and electron microscopy revealed 
the presence of bile canaliculi. Real-time PCR results also showed differential 
regulation in genes involved in liver function, CYP450 enzymatic activities, 
and liver specific transcription factors. Immunofluorescence staining 
demonstrated that these cells had liver specific markers and were positive for 
HLA-G too. Functionally, these cells secreted albumin in vitro, exhibited 
inducible CYP2C9 and CYP3A4 enzymatic activities, were able to uptake and 
clear indocyanine green, and uptake low-density lipoprotein. These hAEC-hep 
cells showed better hepatocytic properties compared to hAEC-raw and hAEC-
epi cells. 
After cellular transplantation into immuno-compromised NOD scid 
gamma mice with thioacetamide induced chronic liver failure, all types of 
hAECs showed engraftment and continued to survive one month post 
transplantation. These cells were HLA-G and albumin positive, indicating that 
despite differentiating into a functional hepatocyte-like cell, they retained their 
immuno-modulatory property. Livers of animals transplanted with either type 
of hAECs were less nodular and less shrunken in morphology and size 
compared to controls. Correspondingly, hAEC transplantation resulted in 
significantly less collagen content detected by Sirius red staining, and down 
regulation of activated hepatic stellate cells as shown by alpha-smooth muscle 
 xiii 
actin immunohistochemical staining. In fact, all transplanted animals showed 
significantly less severe liver injury and improved prothrombin time, but only 
hAEC-epi and hAEC-hep cell transplantation exerted increased synthetic 
functional effect, and only hAEC-hep cell transplantation improved liver 
excretory effect.  
In elucidating the mechanism of action of hAECs, we determined that 
all types of hAECs were able to regress hepatic fibrosis and the mechanism 
appeared to be differentiation of the amniotic derived cells into liver 
sinusoidal endothelial cells in vivo, which in turn promoted quiescence of 
hepatic stellate cells, the main culprit in liver fibrosis. hAEC transplantation 
also caused an upregulation in genes associated with the activation of Ly6Clo 
macrophages, a pro-fibrolysis macrophage population and a modulation in 
mRNA levels of collagen-degrading and collagen-depositing matrix 
metalloproteinases 9 and 12 respectively.  
In this study, we showed for the first time that cells derived from 
human amniotic epithelial membrane at different stages of hepatic 
differentiation were able to reverse liver cirrhosis and lead to improvements in 
clinical correlates of liver cirrhosis via various mechanisms. We also 
concluded that hAEC-hep cells showed the best hepatic function in vitro, and 
exerted more superior effects to chronic liver failure in vivo, compared to 
hAEC-raw and hAEC-epi cells.   
hAECs were able to differentiate into functional hepatocyte-like cells 
both in vivo and in vitro, augmenting liver synthetic, excretory and 
coagulation functions. Contribution to the non-parenchymal liver fraction 
resulted in immunological mediation and reversal of liver cirrhosis. Their 
 xiv 
therapeutic efficacy in our mouse model of cirrhosis provided an encouraging 
basis for their potential use as an exciting source of cells for the treatment of 
liver cirrhosis in humans. 
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Chapter 1 Introduction 
1.1 Background 
Liver failure constitutes a major cause of mortality worldwide. The 
World Health Organization reported almost 980,000 deaths due to liver 
cirrhosis in 2011, and estimates an increase to 1.2 million deaths in 2030 
(World Health Organisation, 2013). The commonest aetiologies of liver 
cirrhosis include hepatitis B and hepatitis C infections, and non-alcoholic fatty 
liver disease. In Singapore, 2.8% of the population carries the hepatitis B virus 
(Hong et al., 2010), and the financial burden of liver related diseases remains a 
major public health issue. The estimated annual costs of chronic hepatitis B 
viral infection and its complications such as liver cirrhosis and hepatocellular 
carcinoma (HCC) amounted to USD 279 million (Ong et al., 2009). Hepatitis 
C is also becoming a serious problem in the world and non-alcoholic fatty 
liver disease is poised to become the most common aetiology for chronic liver 
disease.  
Regardless of the aetiology, liver cirrhosis is the common end-point of 
chronic liver inflammation and results in clinical decompensation and 
increased incidence of liver cancer. The only curative treatment for advanced 
decompensated cirrhosis remains to be liver transplantation, but organ 
donation does not meet the growing demands (Scientific Registry of 
Transplant Recipients, 2011, Williams, 2006). As a result, a substantial 
number of patients die while waiting for an organ to be made available to 
them. This imbalance in supply and demand has driven the urgency to explore 
alternative treatment options for patients with liver cirrhosis.  
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Liver cellular therapy has been an area of great interest in the past two 
decades, and increased understanding about liver repair and regenerative 
mechanisms have provided a basis for usage of cell-based therapies in clinical 
settings (Huebert and Rakela, 2014). Human amniotic epithelial cells (hAECs) 
have been touted to be a good cell candidate for derivation of hepatocyte-like 
cells. These cells originate from the fetal epiblast, and forms a continual 
membrane surrounding the placenta on the fetal-facing side (Miki et al., 
2005). This placental cell expresses stem cell genes which are important in 
self-renewal and pluripotency (Keith L. Moore, 1998). It has also been 
reported that hAECs have the potential of differentiating into cells of all three 
germ layers (Diaz-Prado et al., 2011), and also hepatocytes (Ilancheran et al., 
2007) and cholangiocytes (Moritoki et al., 2007). As the placenta is an 
immuno-privileged site, hAECs are immunologicaly naïve and do not express 
telomerase (Fukuchi et al., 2004), making them less prone to tumorigenic 
transformation and safer for transplantation. Therefore, hAECs hold great 
promise in becoming an ideal cell source for the generation of functional 
hepatocyte-like cells.  
Other cell candidates include human hepatocytes from marginalized 
livers (Dhawan et al., 2010, Horslen et al., 2003), fetal liver cells (Dan et al., 
2006, Tanaka and Miyajima, 2012), embryonic stem cells (Basma et al., 
2009), induced pluripotent stem cells (Si-Tayeb et al., 2010), bone-marrow 
derived hematopoietic stem cells (Oh et al., 2007) and mesenchymal stem 
cells (Kharaziha et al., 2009). However, these candidates are commonly 
confounded by issues such as ethical concerns, potential immune rejection and 
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sub-optimal hepatocytic function. It is therefore imperative to explore other 
cell-sources that can generate hepatocyte-like cells.   
 
1.2 Study Hypothesis 
Human amniotic epithelial cells are plentiful and a non-controversial 
source since the placenta is otherwise discarded after parturition. Hence, using 
this tissue for research purposes would have minimal ethical considerations 
once patient consent is obtained. hAECs are phenotypically plastic and already 
possess some hepatic characteristics in their de novo state (Miki et al., 2005). 
The large cell numbers would also be advantageous for both clinical and 
pharmaceutical applications.  
The ability to maintain these cells in vitro would allow for expansion 
and characterisation of hAECs phenotypically, genotypically and functionally. 
By mimicking the natural development in liver and applying soluble growth 
factors into the in vitro culture environment, we hypothesise that hAECs have 
the ability to be differentiated into functional hepatocyte-like cells. We also 
hypothesise that hepatic differentiated hAECs would exert physiological 
improvements to an animal model with liver cirrhosis.  
 
1.3 Overall aims of study 
The overall aims of this study were: 
1. To isolate and culture hAECs from the placental tissue for 
characterisation. 
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2. To explore an effective method of differentiating hAECs into 
hepatocyte-like cells. 
3. To demonstrate the hepatic genetic signature and functional 
capabilities of differentiated hAECs in vitro. 
4. To investigate if hAECs are able to exert therapeutic benefit in 
animal models of cirrhosis, focusing especially on the 
reversibility of clinical indices of liver dysfunction as well as 
liver fibrosis. 
5. To compare the relative efficacy of hAECs at different stages of 
hepatic differentiation to determine the optimal strategy of 
cellular transplantation with reference to engraftment potential, 
immunomodulation to attenuate fibrosis, improvement of 
hepatocytic function and escape from rejection. 
6. To elucidate the mechanism of action of the in vivo therapeutic 
benefits of hAECs. 
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Chapter 2 Literature Review 
 
Clinical liver disease arises from three main problems, namely 
hepatocyte insufficiency that leads to liver failure, portal hypertension due to 
cirrhosis of the liver and increased liver carcinogenesis due to the proliferative 
and noxious environment of fibrosis. A common complication of progressive 
liver disease is fibrosis, thus it is critical to target and even reverse the fibrotic 
environment before hepatocyte insufficiency and portal hypertension can be 
addressed by treatment. Some strategies of treatment include:  
i. Expand stem cells in vitro for transplantation into patients to replace 
hepatocyte insufficiency. 
ii. The critical need for the fibrotic environment to provide conditions 
optimal for stem cell engraftment and proliferation  
iii. To shut-off hepatic inflammation for transplanted cells to survive  
iv. Reversal of liver fibrosis to reverse complications of portal 
hypertension 
 In this chapter, we discuss the current view points of liver fibrosis and 
regression, various candidates for cellular therapy of liver diseases, and 
analyse why hAECs will make good cell candidates for liver cellular therapy. 
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2.1 Liver fibrosis 
2.1.1 Fibrosis characterization and progression 
The liver responses to hepatic injury through deposition of 
extracellular matrix (ECM), mainly collagen, as a wound-healing mechanism 
(Bataller and Brenner, 2005, Pellicoro et al., 2014). In animal studies, collagen 
deposition and fibrotic scarring has been shown to protect hepatocytes against 
various toxic agents (Bourbonnais et al., 2012). However, prolonged injury 
and long term ECM deposition will lead to liver cirrhosis, which is 
characterised by severely compromised liver architecture that is replaced by 
scar tissue. This disrupts hepatic blood flow and liver function, and would lead 
to complications such as portal hypertension, ascites, liver failure and 
increased susceptibility to HCC (Nusrat et al., 2014). Liver cirrhosis is also a 
common end point for chronic liver injury from various aetiologies such as 
viral infections, non-alcoholic fatty liver disease (NAFLD) and alcohol related 
liver diseases. 
Hepatic inflammation precedes fibrotic progression. During an insult, 
damage to hepatic cells leads to the release and cascade of inflammatory 
mediators that recruit leukocytes, and these cells in turn release more pro-
inflammatory cytokines such as tumour necrosis factor (TNF) and interleukin-
6 (IL-6) (Bataller and Brenner, 2005). These pro-inflammatory cytokines, 
together with the release of reactive oxygen species (ROS) and cell contents 
during cellular apoptosis, causes the activation of quiescent hepatic stellate 
cells (HSCs) into activated myofibroblasts. Quiescent HSCs reside in the 
space of Disse between endothelial cells and hepatocytes, and express neural 
markers such as desmin and glial fibrillary acidic protein (GFAP) (Wang et 
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al., 2013, Yi and Jeong, 2013). Once activated, HSCs transdifferentiate into 
myofibroblasts and become the main collagen-producing cell type during 
fibrosis progression. They lose their neural marker signature, and acquire 
mesenchymal markers such as alpha-smooth muscle actin (αSMA) (Iwaisako 
et al., 2012). 
Macrophages also play an important role in hepatic fibrogenesis. In a 
fibrotic liver, macrophages have been found to closely localise with activated 
myofibroblasts (Duffield et al., 2005, Fallowfield et al., 2007). Duffield et al. 
also showed that when macrophages were conditionally depleted in mice 
undergoing carbon tetrachloride (CCl4) induced liver injury, a reduction in the 
number of activated myofibroblasts was seen and fibrosis was decreased 
(Duffield et al., 2005). In the liver, macrophages can be categorised into 
resident Kupffer cells or circulating monocyte-derived macrophages (Holt et 
al., 2008). Kupffer cells first respond to liver injury by secreting chemokines 
such as chemokine (C-C motif) ligand 2 (CCL2), which recruits circulating 
monocytes. The Ly6Chi macrophage population has also been identified as the 
predominant subset of monocyte-derived macrophages during fibrogenesis, 
and they exert a triple effect on fibrosis progression (Karlmark et al., 2009, 
Pellicoro et al., 2014). Firstly, they express transforming growth factor-β 
(TGFβ), which activates quiescent HSCs into activated myfibroblasts (Wynn 
and Barron, 2010). Secondly, they produce platelet-derived growth factor 
(PDGF) which stimulates the proliferation of activated myofibroblasts (Wynn 
and Barron, 2010). Thirdly, they release pro-inflammatory TNF which have 
been shown to promote the survival of activated myofibroblast, therefore 
perpetuating liver fibrosis (Pradere et al., 2013). However, macrophages have 
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also been shown to play an important role in fibrosis resolution, making the 
involvement of macrophages in hepatic fibrosis a more complex one.  
 
2.1.2 Fibrosis resolution 
Liver fibrosis is a dynamic process, and even in advance disease, 
reversal of fibrosis is possible (Iwaisako et al., 2012, Ramachandran et al., 
2012). This could be acheived by either removing the injury stimuli, degrading 
excess ECM deposition or reducing the number of activated myofibroblasts.  
By eliminating primary causes of chronic liver injury such as hepatitis 
infection and alcohol related liver diseases using drugs and a change in 
lifestyle, the injury stimulus is removed. As a result, fibrogenesis will no 
longer be aggravated, allowing for resolution of fibrosis to occur (Pellicoro et 
al., 2012b, Ramachandran and Iredale, 2009). 
Macrophages also play an important role in fibrosis regression as they 
are a rich source of fibrolytic matrix metalloproteinases (MMPs) such as 
MMP9 (Pellicoro et al., 2012a, Ramachandran and Iredale, 2012). These 
MMPs are collagenases that degrade collagen ECM, and improvement of 
fibrosis can be seen once scar tissue is resolved (Hemmann et al., 2007). 
Ramachandran et al. reported that the Ly6Chi macrophage population undergo 
a phenotypic switch to a predominantly Ly6Clo population during fibrosis 
resolution in murine animals (Ramachandran et al., 2012). This macrophage 
population increased MMP content in the liver, enhanced anti-inflammatory 
properties through increased expression of chemokine (C-X3-C) receptor 1 
(CX3CR1), and heightened anti-fibrotic effects by increased macrophage 
migratory inhibiting factor (MIF) and CD74. This dual effect of macrophages 
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in fibrogenesis and fibrolysis is an intriguing one, and perhaps the key to 
determining which process occurs depends on the balance of these pro- or 
anti-fibrotic macrophages.  
Fibrolytic Ly6Clo macrophages also express TNF-related apoptosis-
inducing ligand (TRAIL), which promotes apoptosis of activated 
myofibroblasts (Ramachandran and Iredale, 2012). Activated myofibroblasts 
express tissue inhibitor of metalloproteinases 1 (TIMP1), which inhibits the 
activity of MMPs. The removal of TIMP1 expression after myofibroblast 
apoptosis enables more MMPs to degrade ECM and resolve fibrosis (Pellicoro 
et al., 2014). Activated myofibroblasts have also been reported to be capable 
of reverting to their quiescent state during fibrosis resolution (Kisseleva et al., 
2012, Troeger et al., 2012). This inactivation was found to be related to the up 
regulation of heat shock proteins, which were involved in the survival of 
hepatic stellate cells. Xie et al. also showed that quiescence of activated 
myofibroblats was due to the restoration of fenestrated liver sinusoidal 
endothelial cells (LSECs) (Xie et al., 2012). LSEC in their fenestrated (or 
differentiated) state promotes the quiescence of HSCs through VEGF-
stimulated nitric oxide (NO) production in vitro (Deleve et al., 2008).  
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Figure 2.1 Summary of fibrosis initiation, progression and resolution.  
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2.2 Candidates for cellular therapy of human liver diseases 
Cell-based therapy has been explored as an alternative treatment 
approach for various human liver diseases due to limitations in whole liver 
transplantation. Currently, well-studied cell candidates include adult 
hepatocytes and fetal liver, as well as extra-hepatic sources like embryonic 
stem cells, induced pluripotent stem cells and mesenchymal stem cells. 
Stem cells are recognized as good cell candidates because they have 
self-renewal properties and can be differentiated into cells of various lineages. 
However, there remains the fear of stem cells transforming into teratomas 
after human transplantation, thus more extensive evaluation of the safety 
profile of these cell candidates needs to be carried out.  
Many of these cell candidates showed good hepatic characteristics in 
vitro and in vivo, and some have been tested in clinical trials. However, the 
clinical efficacy of these cells remains to be enhanced as they often yield 
short-lived and limited improvements (Dan, 2012). Differences in methods of 
cell isolation and patient disease aetiology also made it difficult for fair 
comparisons between various clinical studies. Ultimately, the biggest 
limitation of these cells remains to be the lack of good quality hepatocytes in 
sufficient quantity. Hence, the search for alternative cell candidates is of 
ongoing interest.   
 
2.2.1 Adult Hepatocytes 
Humans are able to survive partial hepatectomy of up to 75% resection 
of the liver mass, and within one week, the total number of liver cells would 
have been restored through the replication of existing hepatocytes (Duncan et 
 12 
al., 2009, Fausto et al., 2012, Mao et al., 2014). Molecular studies have shown 
that cytokines such as IL-6 and TNF initiate the activation of numerous early 
genes involved in regeneration, leading to DNA synthesis, cell replication and 
increase in cell size (Li et al., 2001, Michalopoulos and DeFrances, 1997). 
Growth factors such as hepatocyte growth factor (HGF) are also important in 
liver regeneration. Produced by HSCs and acting on a paracrine and endocrine 
manner on hepatocytes, HGF activates extracellular signal-mediated kinases 
1/2 (ERK 1/2) which leads to hepatocyte proliferation (Borowiak et al., 2004, 
Huh et al., 2004, Michalopoulos and Khan, 2005).  
Transplantation of rodent adult hepatocytes into rats with portacaval 
shunts showed improved urea production and decreased serum L-histidine 
concentrations, resulting in improved liver function and encephalopathy 
(Fogel et al., 2014). In another study, transplanted human hepatocytes 
engrafted up to 92% of livers of urokinase-type plasminogen activator-
transgenic severe combined immunodeficiency (uPA-SCID) mice (Tateno et 
al., 2004). In human studies, patients with acute-on-chronic liver failure 
(Wang et al., 2014), Wilson’s diseases (Filippi and Dhawan, 2014), 
phenylketonuria (Stephenne et al., 2012) and urea cycle disorder (Horslen et 
al., 2003) received transplantations of human adult hepatocyte and some saw 
improved outcomes.  
However, due to limited supply of suitable donor livers, high cell 
number requirement for each transplantation (typically 2 billion cells to aim 
for a 2.5% engraftment (Wang et al., 2014)), and limited ability of hepatocyte 
expansion in vitro, hepatocyte transplantation has not been able to achieve full 
clinical usage. Further studies on how to provide transplanted cells the 
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engraftment and expansion advantage over endogenous hepatocytes also needs 
to be carried out in order to improve the clinical efficacy of hepatocyte 
transplantation (Puppi et al., 2012, Vogel et al., 2014).  
 
2.2.2 Fetal liver 
Majority of our knowledge on fetal liver cells were derived from 
research done on rodent models. In rats, fetal liver cells have demonstrated 
extensive proliferative and reparative capabilities following 20% partial 
hepatectomy (Elchaninov and Bolshakova, 2011). Transplantation of fetal 
liver stem/ progenitor cells (FLSPC) isolated from rodent embryonic fetuses 
into animals with liver injury had shown repopulation and hepatic functional 
integration (Cantz et al., 2003, Oertel et al., 2008, Sandhu et al., 2001, Zhang 
et al., 2009). Rodent fetal liver cells also had bipotential differentiation 
capabilities, giving rise to both hepatocytes and biliary epithelium (Germain et 
al., 1988, Rogler, 1997).  
In humans, fetal liver cells were isolated using various cell surface 
markers such as epithelial cell adhesion molecule (EPCAM) (Dan et al., 2006, 
Schmelzer et al., 2007) or CD177+/CD34+/Lin- cell sorting (Nowak et al., 
2005). These cells were bipotential, withstood cryopreservation and could 
repopulate injured livers of animal models. Success in long-term maintenance 
of these cells in vitro has also been achieved (Chinnici et al., 2014, Lazaro et 
al., 2003). MicroRNAs such as miR-122 have also been implicated in 
differentiation of fetal liver cells, and interest has been gained on how to 
capitalise on this miR-122 molecule to enchance hepatic differentiation 
(Callegari et al., 2015, Chen et al., 2010, Doddapaneni et al., 2013). However, 
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rat FLSPCs remains to be the only cell type that can effectively repopulate and 
integrate into an adult liver (Oertel, 2011), even in the absence of an injury 
stimulus (Oertel et al., 2006). 
Till date, no known clinical trials involving human fetal liver cells 
have been carried out (Esrefoglu, 2013). The ethical barrier of harvesting 
livers from fetuses is one that is difficult to overcome, and access to such 
tissue samples is very limited. The lack of sufficient, good quality cells 
required for transplantation could also be a reason why human fetal liver cells 
are not used in the clinical setting for therapy yet.  
 
2.2.3 Embryonic stem cells 
Embryonic stem cells (ESCs) are derived from the inner cell mass of a 
blastocyst, and possess key characteristics such as unlimited self-renewal 
capacity and pluripotency (Basma et al., 2009, Zhou and Huang, 2011). 
Numerous hepatic differentiation protocols for ESCs have been established, 
including methods using step-wise culture supplemented with activin A, 
fibroblast growth factor 2 (FGF2), FGF4, bone morphogenetic protein 4 
(BMP4), HGF and oncostatin M (Agarwal et al., 2008, Cai et al., 2007), 
spheroid culture for enhanced hepatic differentiation (Subramanian et al., 
2014), scaling-up protocols using microcarriers (Park et al., 2014) and xeno-
free extracellular matrix (Farzaneh et al., 2014).  
Differentiated ESCs possess hepatic gene and protein signatures such 
as albumin, alpha-fetoprotein (AFP), hepatocyte nuclear factor 4 (HNF4) and 
anti-asialoglycoprotein receptor 1 (ASGPR-1) (Farzaneh et al., 2014, Park et 
al., 2014, Subramanian et al., 2014). Functionally, these cells displayed 
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albumin and urea secretion, CYP3A4 enzymatic activity, glycogen storage, 
low-density lipoprotein (LDL) uptake and AFP secretion (Farzaneh et al., 
2014, Park et al., 2014, Subramanian et al., 2014). Transplantation of hepatic 
differentiated ESCs into rodent models of liver injury showed measurable 
improvements in serum albumin and bilirubin levels (Heo et al., 2006, 
Teratani et al., 2005, Yamamoto et al., 2003), and showed successful cellular 
engraftment of up to 2% efficiency (Basma et al., 2009, Duan et al., 2007, 
Haridass et al., 2009, Kumashiro et al., 2005, Yamamoto et al., 2003). 
Despite these successes, the ethical concerns that shroud ESCs remains 
to be a hindrance for the translation of these cells from bench to bedside. In 
2009, the U.S. Food and Drug Administration (FDA) approved its first phase I 
trial involving ESCs for treatment of patients with severe spinal cord injury 
(Alper, 2009), after many years of advancement in ESCs technologies. This 
conservative approach is logical as these cells were derived from the 
blastocyst, but this requires for the destruction of an embryo and a potential 
human life (Manzar et al., 2013). This is widely considered as unethical.  
Moreover, the difficulty in obtaining enough cell numbers as well as 
possibility of teratoma formation remains a big challenge for ESCs 
(Yamamoto et al., 2003). 
 
2.2.4 Induced pluripotent stem cells 
Induced pluripotent stem cells (iPSCs) was first described by 
Yamanaka et al. in 2007, an elegant experiment involving retroviral 
overexpression of four key genes in mouse adult fibroblasts – Octamer-
binding transcription factor 3/4 (Oct-3/4), SRY (Sex Determining Region Y)-
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Box 2 (SOX2), c-Myc and Kruppel-Like Factor 4 (KLF4) (Takahashi and 
Yamanaka, 2006). Reprogrammed iPSCs clustered closely to ESCs in DNA 
microarray analysis and formed teratoma in immunodeficient nude mice. 
Methods that eliminated the use of viral vectors were also devised (Okita et 
al., 2008), and the reprogramming method was also quickly applied 
successfully to human cells (Park et al., 2008, Takahashi et al., 2007). 
Subsequently, c-Myc was removed from the reprogramming protocol, and this 
greatly decreased the tumorigenecity of iPSCs (Nakagawa et al., 2008).  
Protocols for hepatic differentiation of mice and human iPSCs have 
also been widely published, and these cells demonstrated hepatic gene profile 
and functions such as albumin secretion, urea production, and inducible 
cytochrome P450 activity (Gai et al., 2010, Mallanna and Duncan, 2013, Si-
Tayeb et al., 2010, Song et al., 2009).  
The biggest advantage of iPSC-derived hepatocytes is the autologous 
nature of prospective transplantation. Fibroblasts can be harvested and 
transplanted back to the same patient, eliminating the chance of immune 
rejection and need for long-term immunosuppression. These cells are also free 
from ethical concerns that surround ESCs. A recent study showed that 
fibroblasts from liver cancer patients can be reprogrammed to iPSCs, albeit 
using a lentiviral vector infection method (Zhang et al., 2014). Nonetheless, 
iPSC-derived hepatocytes hold great promise in future cellular therapy for 
patients with liver disease. When human iPSC generation and its hepatic 
differentiation can be achieved using non-viral methods, iPSC-derived 
hepatocytes may one day become a viable treatment option in the clinical 
setting.   
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2.2.5 Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) are adult stem cells that can be found 
in various tissues including the bone marrow and adipose tissues (Esrefoglu, 
2013).  
Bone marrow-derived MSCs (BM-MSCs) was first thought to be able 
to transdifferentiate into hepatocytes when Lagasse et al. showed hepatic 
regeneration after transplantation of these cells into fumarylacetoacetate 
hydrolase knockout mice (Lagasse et al., 2000). This reparative process was 
later disproved as a fusion event of the myelo-monocytic subpopulation of 
BM-MSCs with host hepatocytes, and not a true transdifferentiation 
occurrence (Willenbring et al., 2004). In other reports, there was evidence that 
hepatocytes or epithelial cells can be derived from BM-MSCs (Lee et al., 
2004, Sato et al., 2005). There has also been in vivo data that transplanted 
BM-MSCs restored rodent serum albumin levels and decreased fibrosis 
(Oyagi et al., 2006), but the contrary of no measurable effect has also been 
shown in another study (Carvalho et al., 2008). There has not been any true 
conclusive evidence that BM-MSCs played an important role in the repair of 
liver injury. The real mechanism behind BM-MSC mediated liver repair has 
been a point of contention and a consensus has not yet been reached in the 
scientific community (Cantz et al., 2004, Kallis et al., 2007, Menthena et al., 
2004, Thorgeirsson and Grisham, 2006).  
With some promising data from animal studies, autologous BM-MSCs 
have been transplanted into human patients. Peng et al. reported that 53 
patients with liver failure cause by hepatitis B had autologous BM-MSCs 
slowly transfused into the liver through the hepatic artery (Peng et al., 2011). 
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After 2-3 weeks post-transplant, patients showed marked improvements in 
albumin levels, total bilirubin levels, prothrombin time and model for end-
stage liver disease (MELD) scores. This study demonstrated the safety of 
autologous BM-MSC transplantation and short-term efficacy, whereas no 
long-term efficacy was seen. Another study by Kharaziha et al. showed similar 
results in a smaller group of 8 patients (Kharaziha et al., 2009). In the field of 
liver decellularisation and artificial liver graft, BM-MSCs were co-cultured 
with hepatocytes and have been demonstrated to support hepatocyte function 
in engineered liver grafts (Kadota et al., 2014).  
Adipose tissue-derived MSCs (AT-MSCs) are easily isolated from fat 
tissues and they have also been shown to be able to transdifferentiate into 
hepatocyte-like cells (Banas et al., 2009, Banas et al., 2008a, Banas et al., 
2007, Seo et al., 2005, Talens-Visconti et al., 2007). Animal studies in rodents 
with acute liver failure also showed decrease in liver injury markers after 
transplantation of AT-MSC derived hepatocytes (Banas et al., 2009). To date, 
there are no published studies on AT-MSC transplantation in human patients, 
but efficacy was shown in porcine model of liver injury (Avritscher et al., 
2013).  The possibility of autologous transplantation, isolation of large 
quantities of cells and even from human donors makes AT-MSCs a plausible 
source of ex vivo hepatocytes for therapy. 
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2.3 Human amniotic epithelial cells (hAECs) 
2.3.1 Stem cell characteristics of hAECs 
The placenta comprises of three layers: decidua, chorion and amnion. 
The decidua is derived maternally, the chorion from the embryonic trophoblast 
and the amnion from the embryonic epiblast. hAECs form the continuous 
membrane of the amnion on the fetal-facing side, surrounding the placenta 
(Miki et al., 2005).  
This placental cell expresses stem cell genes that are important in self-
renewal and pluripotency such as stage-specific embryonic antigen (SSEA)-3, 
-4, Oct-4, nanog homeobox (NANOG) and SOX2 (Keith L. Moore, 1998, 
Miki et al., 2005). They have also been described to differentiate into all three 
germ layers in vitro (Diaz-Prado et al., 2011, Keith L. Moore, 1998, Miki et 
al., 2005), and maintained their stem cell characteristics up to four passages 
(Evron et al., 2011). hAECs also do not express telomerase (Miki et al., 2005), 
suggesting that hAECs have a low possibility of transforming into tumorigenic 
cells, unlike ESCs of iPSCs. Indeed, when hAECs were transplanted into 
livers of SCID/beige or Rag2-/- mice, none of the recipients developed 
tumours, and they even started producing human albumin (Marongiu et al., 
2011, Miki et al., 2005, Takashima et al., 2004).  
 
2.3.2 Hepatic differentiation of hAECs 
Takashima et al. described that raw, freshly dissociated hAECs already 
possess some hepatic genetic markers such as albumin, alpha-1-antitrypsin 
(α1AT) and CYP3A4, and hepatic functions such as glycogen storage 
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(Takashima et al., 2004). However, various methods of hAEC hepatic 
differentiation have also been describe in literature. The most common method 
used dexamethasone, insulin, phenobarbital, HGF and oncostatin M 
(Ilancheran et al., 2007, Luo et al., 2011, Miki et al., 2005, Takashima et al., 
2004). Marongiu et al. described a different method that sandwiched hAECs 
between either porcine liver-derived ECM (L-ECM) or matrigel. Further 
differentiation was then done using FGF-2, dexamethasone, 
insulin/transferrin/selenium (ITS) premix and oncostatin M (Marongiu et al., 
2011).  
Differentiated cells showed mRNA and protein expression of hepatic 
genes such as albumin, α1AT, CYP3A4, CYP3A7, CYP7A1, and HNF-4α. 
Cells also showed some functional capabilities such as albumin secretion, 
ammonia metabolism and inducible CYP1A enzymatic activity. Freshly 
dissociated hAECs or pieces of the amnion have been transplanted into 
immunodeficient rodent models, where hAECs differentiated into hepatocyte-
like cells in vivo (Marongiu et al., 2011, Takashima et al., 2004). 
Immunostaining of mouse livers were also positive for albumin, CYP3A4 and 
CYP2E1.  
To date, no clinical studies have been done to assess the efficacy of 
hAEC transplantation into human patients with liver disease. However, as 
early as 1981, human volunteers were transplanted with human amniotic 
epithelial membranes subcutaneously. No acute rejection was reported in all 7 
volunteers, and donor cells were detected from biopsies up to 7 weeks post-
transplantation (Akle et al., 1981). This, to a certain extent, shows that hAECs 
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are compatible with allogenic transplantation without causing immune 
rejection.   
 
2.3.3 Immunogenicity of hAECs 
The placenta, which is situated at the interface of maternal and fetal 
immune systems, is considered an immuno-privileged site. As the fetus has 
half of his/ her genes from the father, he/ she is considered an allograft to the 
mother and the placenta needs to have processes of immune suppression or 
tolerance to protect the fetus from a maternal immune attack. 
Freshly dissociated hAECs have been shown to express very low 
levels of major histocompatibility complex (MHC) class I molecules- HLA-A, 
-B, -C, and negligible levels of MHC class II molecules- HLA-DP, -DQ, -DR 
(Adinolfi et al., 1982, Akle et al., 1981, Banas et al., 2008b, Diaz-Prado et al., 
2011, Ilancheran et al., 2007).  These MHC molecules are responsible for 
antigen presentation to T cells (Parham and Ohta, 1996), and in its absence/ 
low presence, hAECs become unrecognizable by maternal T cells and evade 
maternal immune surveillance. Li et al. reported that in vitro culture 
supernatants of hAECs inhibited chemotactic activity of neutrophils and 
macrophages towards macrophage inflammatory protein-2 (MIP-2) due to the 
secretion of macrophage migration-inhibitory factor (MIF) by hAECs. These 
cells also significantly reduced the proliferation of B and T cells after 
mitogenic stimulation, partly due to the expression of Fas ligand that induced 
lymphocyte apoptosis (Li et al., 2005). 
In 1986, a novel HLA antigen was discovered in extravillous 
trophoblasts (EVTs) described as a nonclassical MHC-Ib antigen (Ellis et al., 
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1986). This was later known as HLA-G and was thought to have a specific 
tissue distribution to EVTs, suggesting its specific functions in immuno-
modulation during pregnancy. HLA-G expression was also identified in 
hAECs (Houlihan et al., 1995, Le Bouteiller et al., 1999). HLA-G exists in 6 
isoforms, of which four are membrane bound and two in soluble forms (Le 
Bouteiller et al., 1999).  They are structurally similar to other MHC-Ia 
antigens and bind to CD8. However, due to it low polymorphism, slow 
turnover and limited tissue distribution, antigen presentation is unlikely the 
primary function of HLA-G (Le Bouteiller and Solier, 2001). 
HLA-G receptors are expressed on immune cells such as antigen 
presenting cells (APCs), T and B lymphocytes and natural killer (NK) cells, 
hence HLA-G interacts and impacts a variety of immune cell types. Rouas-
Freiss et al. showed that HLA-G inhibits proliferation and cytokine functions 
of uterine and peripheral blood NK cells, providing direct evidence that HLA-
G protects fetal cells from uterine NK cell cytolysis (Rouas-Freiss et al., 
1997). HLA-G inhibits proliferation of both CD4+ and CD8+ T cells (Bahri et 
al., 2006), and has been suggested to induce the development of tolerogenic 
dendritic cells, which then induces the differentiation of anergic and 
immunosuppressive effector T cells (Ristich et al., 2005, Smith et al., 2008). 
Interestingly, renal and gastric tumour cells upregulate the expression of HLA-
G, using its immunosuppressive properties to evade immune surveillance in 
vivo, and expression of HLA-G correlates with poor prognosis in gastric 
carcinoma (Ibrahim et al., 2001, Yie et al., 2007).  
When hAECs were transplanted into C57BL/6 mice with liver fibrosis, 
these cells successfully engrafted in the mouse livers without signs of immune 
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rejection, expressed HLA-G and decreased liver inflammation and fibrosis 
(Manuelpillai et al., 2010). The same research group went on to show that 
hAECs induced markers of activated M2 macrophages, thereby reducing 
hepatic fibrosis (Manuelpillai et al., 2012). Transplantation of hAECs into 
rodent models also saw correction in hepatic metabolic diseases such as maple 
syrup urine disease (Skvorak et al., 2013a, Skvorak et al., 2013b). 
 
2.3.4 hAECs as an ideal cell source for therapy of liver diseases  
After understanding the many properties of hAECs, the reasons why 
hAECs holds the promise of being an ideal ex vivo source for liver cellular 
therapeutics are listed as follows: 
1. In their raw, de novo state, hAECs possess some hepatocytic 
genetic markers. Being fetal in origin, they also had ease of 
differentiation into all three germ layers, including hepatocytes.  
2. hAECs lack MHC class I molecules, and have negligible MHC 
class II molecules, making them immunologically naïve and ideal 
for transplantation due to their ability to evade host immune 
rejection. 
3. hAECs display immuno-modulatory properties (HLA-G), and have 
been shown to reduce fibrosis and reverse hostile inflammatory 
environments in rodents.   
4. hAECs do not express telomerase, and hence, are postulated to be 
safe for transplantation. Animal studies also found no formation of 
teratomas after transplantation. 
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5. The placenta is a large tissue and yields large quantities of hAECs 
that is pivotal for human transplantation.  
6. hAECs are harvested from a non-contentious origin, the placenta. 
This extra-embryonic tissue is otherwise discarded after childbirth, 
and does not possess ethical concerns unlike ESCs and fetal liver 
cells. 
 
2.3.5 Current gaps of knowledge in hAEC treatment of liver 
diseases 
Although several hAEC hepatic differentiation protocols have been 
published, most lacked detailed descriptions of methods especially on the 
duration of in vitro differentiation. There is also a lack of comprehensive 
assessment of phenotype, genetic profile and function of hepatic differentiated 
hAECs. Hence, we sought to develop a systematic and reliable diffrentiation 
protocol that is free from animal additives, characterise hepatic differentiated 
hAECs, and also compare them with freshly dissociated hAEC cells in their de 
novo state. 
In literature, a large majority of in vivo work described only the effects 
of freshly dissociated hAECs in rodent models of liver diseases. There is a 
lack of reports on the efficacy of in vitro hepatic differentiated hAECs in 
animal models, and also specifically in a chronic liver injury model. There is 
also a lack of comparison between the effects of hepatic differentiated and de 
novo hAECs after transplantation. Hence, we sought to investigate and 
compare their in vivo effects in both chronic and acute liver injury models. 
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Given its intrinsic advantage as a potential stem cell candidate, we 
hypothesise that: 
1. hAECs may be therapeutically useful in vivo via one of the 
following mechanisms:  
i. Differentiation into hepatocytes to augment liver 
insufficiency 
ii. Repair and reversal of the cirrhotic environment  
iii. Immunological mediation to attenuate injury  
 
2. These therapeutic benefits are demonstrable in an in vivo model 
in terms of reversal of clinical correlates of cirrhosis and liver 
failure. 
 
3. In vitro hepatic differentiated of hAECs may be more useful 
than de novo hAECs without sacrificing the immunological 
property of immune escape and injury mediation .  
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Chapter 3 In vitro characterisation of hAECs 
3.1 Introduction 
Wallace et al. described that hAECs isolated from preterm placentas 
had limited anti-inflammatory and reparative potential compared to term 
placentas (Lim et al., 2013). In this study, only term placentas were collected 
from consenting patients, and hAECs were isolated from them.  
We characterised freshly dissociated hAECs in their de novo state 
(from here on termed hAEC-raw) in terms of morphological and growth 
characteristics, expression of hepatocytic genetic and immunological markers, 
and glycogen storage as a form of functional study. This allowed for cross 
referencing of our cells with the characteristics described in literature.  
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3.2 Materials and methods 
3.2.1 Isolation and in vitro maintenance of hAEC-raw cells 
The study centre for this project was at the National University 
Hospital of Singapore (NUH). Informed patient consent was obtained by a 
research nurse from pregnant women scheduled for elective lower segment 
cesarean sections at full term. Researchers were blinded from patient 
identities.  
The amniotic epithelial membrane was peeled off from the placenta 
body, starting from the area closest to the umbillical cord. This was performed 
in the operating theatre under sterile conditions to prevent contamination, and 
tissues collected were transported back to the laboratory for dissociation. 
Method of dissociation was according to the protocol published by 
Miki et al. (Miki et al., 2010). In brief, tissues were digested in 1x Trypsin/ 
EDTA (PAA Co.) for 40 minutes, twice. Cells collected from each round of 
digestion were washed with phosphate buffered saline (PBS; Vivantis 
Technologies), centrifuged at 200g for 10 minutes at 4°C and cultured at a 
density of 0.8 × 105 cells per cm2.  
hAEC-raw cells were cultured on uncoated plastic petri dishes, and in 









DMEM (high glucose) 500ml Invitrogen 
Epidermal growth factor (EGF) 20ng/ml BD Biosciences 
ITS premix 1:1000 dilution BD Biosciences 
Sodium Pyruvate 1mM Gibco 
Sodium Bicarbonate 0.15% solution Gibco 
HEPES 10mM Gibco 
Glutamax 1x Gibco 
Ascorbic acid 0.2mM Sigma-Aldrich 
 
3.2.2 Phase contrast microscopy 
Cells were viewed under phase contrast microscopy for observations of 
cell morphology and Periodic acid- Schiff staining, using an Olympus IX70 
microscope. Pictures were captured using a Olympus E-510 DSLR camera.  
 
3.2.3 Alamar blue assay 
Alamar blue assay was carried out on hAEC-raw cells every day from 
day one to five of culture, immediately after dissociation. 10% alamar blue 
solution (Invitrogen) was added to complete-DMEM, and incubated for one 
hour at 37°C. Media was then collected and fluorescence intensities were 
measured using the TECAN GENios fluoremeter, at a excitation wavelength 
of 565nm and emission wavelength of 595nm. 
Cells were washed with PBS, and returned to fresh complete-DMEM 
for further growth.  
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3.2.4 Polymerase chain reaction (PCR) 
Total RNA was isolated from hAECs using standard Trizol method. 
Total RNA was quantified using Nanodrop 1000 spectrophotometer. 100ng of 
RNA was used for reverse transcription to cDNA using the RT2 First Strand 
Kit (Qiagen), following manufacturer’s recommendations. 
PCR was performed using EconoTaq PLUS GREEN master mixes 
(Lucigen), using standard cycling conditions recommended by the 
manufacturer. PTC-100 programmable thermal controller (MJ Research Inc.) 
was used to run the reactions. Primers used were purchased from AITbiotech, 
and details are listed below. 
 
Table 2 Primers used in chapter 3. 


















3.2.5 Paraffin sections 
Tissue samples were fixed in 4% formaldehyde (ICM Pharma) and 
sent to NUH pathology laboratory for embedding into paraffin blocks. Tissue 
sections were cut at 3µM thickness using a Leica RM2255 rotary microtome, 




Freshly dissociated hAEC-raw cells were spun onto polysine coated 
glass slides (Thermo Fisher Scientific) using the Shandon Cytospin 4 
cytocentrifuge. 5000-10,000 cells were resuspended in 300µl of PBS, and 
loaded into individual cuvettes attached to glass slides. Cells were spun at 800 
rpm for three minutes, and slides were fixed in acetone (Sigma-aldrich) at -
20°C for 10 minutes. 
 
3.2.7 Immunofluorescence staining  
Tissue sections were dewaxed using three changes of xylene (Merck) 
at 5 minutes each, then rehydrated in 100%, 90% and 70% ethanol 
sequentially (Thermo Fisher Scientific), each for one minute. Slides were 
boiled in antigen retrieval solution (DAKO) at 120°C for five minutes, 
quenched using 0.1M glycine (Sigma-Aldrich) at room temperature for 10 
minutes, then blocked in 10% natural horse serum (Gibco) at room 
temperature for one hour.  
Primary antibodies used in this section are listed below, and secondary 
antibodies used were Alexa Fluor 488 of 568 (Invitrogen). Dapi staining was 
done using dapi fluorescent mounting media (Santa Cruz Biotechnology). 
Slides were viewed using a Olympus BX60 epifluorescence microscope.  
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HLA-G Mouse 1:100 
1 hour/  
Room temperature 
BD Pharmingen 
Oct-4 Rabbit 1:200 Overnight/ 4°C Sigma-aldrich 
E-cadherin Mouse 1:100 Overnight/ 4°C Zymed 
EPCAM Rabbit 1:100 Overnight/ 4°C Novus (SDIX) 
 
3.2.8 Periodic acid- Schiff staining 
Periodic acid- Schiff (PAS) staining was performed to detect glycogen 
stored in the cytoplasm of hAEC-raw cells. Cells were first cultured for three 
days, then fixed in acetone (Sigma-aldrich) at -20°C for 10 minutes.  
For negative control slides, cells were first treated with 0.5% diastase 
solution (Sigma-aldrich) for 20 minutes. Experimental slides had this step 
omitted. 1% periodic acid (Sigma-aldrich) was then added to cells and 
incubated for 10 minutes at room temperature, followed by two washes with 
tap water. Sciff’s fuchsin-sulfite reagent (Sigma-aldrich) was then added, and 
incubated again for 10 minutes at room temperature. Cells were washed with 
tap water twice, and purple colourization was visualized using the phase 




3.3.1 Growth properties of hAEC-raw cells 
After trypsinization, each placental tissue could yield between 20-50 
million hAEC-raw cells. These cells attached to plastic surfaces of petri 
dishes, and proliferated robustly in vitro (figure 3.1).  
Majority of the seeded cells attached after one day of culture. At day 
three, hAEC-raw cells started to display a typical epithelial morphology, and 
showed proliferation. Most of the non-adherent cells were also washed off by 
this day. At day 5, cells have reached confluence and still maintained its 
epithelial morphology. hAEC-raw cells were passaged at a fold dilution of 1:3 
when confluency was reached, usually after five days in culture. The doubling 





Figure 3.1 Morphology of hAEC-raw cells in culture.  
A: At day one after seeding, hAEC-raw cell attached successfully to the 
plastic surface of petri dishes. Some non-adherent, floating cells still remained 
in the culture media. B: After three days in culture, cells exhibited 
proliferation and displayed epithelial morphology. Most non-adherent cells 
were also washed off by now. C: hAEC-raw cells proliferated to confluence 
after 5 days in culture, and still maintained its epithelial morphology (phase 





Figure 3.2 Alamar blue assay for doubling time of hAEC-raw cells.  
Alamar blue assay showed a doubling of fluorescence intensity between day 1 























3.3.2 Hepatic genotype of hAEC-raw cells 
We performed PCR to validate if hAEC-raw cells possessed any 
hepatic genetic expression. Contrary to that described by Takashima et al. 
(Takashima et al., 2004), our hAEC-raw cells were negative for human 
albumin, CYP3A4 and AFP hepatic genes (figure 3.3). This discrepancy could 





Figure 3.3 Hepatic genotype of hAEC-raw cells.  




3.3.3 Immunophenotype of amniotic epithelial membrane (tissue) 
and hAEC-raw cells 
Fluorescent immunostaining was performed on the amniotic epithelial 
membrane tissue to examine its de novo immunophenotype. Immunostaining 
was also performed on cytospun hAEC-raw cells to ensure that the dissociated 
cells had consistent immunophenotype as their de novo membranous tissues.  
Human amniotic epithelial membrane showed HLA-G 
immunophenotype, a unique cell surface marker involved in 
immunomodulation, as well as an important marker for subsequent cell tracing 
after transplantation into rodent models (figure 3.4). They were also positive 
for stem cell marker Oct-4, which indicated its potential for pluripotency. 
Being epithelial cells by nature, the tissue stained positive for epithelial 
markers EPCAM and E-cadherin (figure 3.5). After dissociation, hAEC-raw 
cells were also positive for all above-mentioned proteins (figures 3.5-3.6), 
demonstrating consistency between the amniotic membrane and dissociated 
cells. . 





Figure 3.4 Immunophenotype of human amniotic epithelial membrane I. 
Immunostaining showed that cells were positive for placental marker HLA-G 






Figure 3.5 Immunophenotype of human amniotic epithelial membrane II. 
Immunostaining showed that cells were positive for epithelial markers 







Figure 3.6 Immunophenotype of hAEC-raw cells I.  
hAEC-raw cells were positive for HLA-G protein after enzymatic 





Figure 3.7 Immunophenotype of hAEC-raw cells II.  
hAEC-raw cells were positive for EPCAM, E-cadherin and Oct-4 proteins 
after enzymatic dissociation, consistent with its de novo membranous form 
(epifluorescence, x60 magnification). 
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3.3.4 hAEC-raw cells stored glycogen 
Takashima et al. previously described that freshly dissociated hAECs 
possess some hepatocytic function such as glycogen storage prior to 
differentiation (Takashima et al., 2004). We investigated this in our hAEC-raw 
cells, and congruent to literature, our cells were able to store glycogen in their 
cell cytoplasm (figure 3.8). To confirm the specificity of the glycogen 






Figure 3.8 PAS staining for glycogen on hAEC-raw cells. 
A: Using PAS staining, hAEC-raw cells showed positive purple staining for 
glycogen storage (phase contrast, x20 magnification). B: With diastase 
pretreatment, the purple colouration was lost, confirming the specificity of the 
glycogen stain (phase contrast, x40 magnification). 
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3.4 Interpretation and conclusion 
We were able to successfully dissociate hAECs from all amniotic 
membranes obtained, giving us a 100% efficiency in hAEC derivation from 
tissue. Each tissue yielded an abundance of 20-50 million cells, and these cells 
showed relatively uniformed morphology after plating in vitro. We expanded 
these cells up to three passages and over time, these cells maintained 
consistent morphology. We did not attempt more than three passages as 
placental tissues were readily available and hAEC-raw cells were plentiful for 
experimental purposes. After expansion, they retained their 
immunophenotype, which will be further described in chapter 4, categorised 
as hAEC-epi cells.  
The amniotic membrane was a single cell layer that peeled off easily 
from the placenta, and one placenta sample generated up to 50 million hAEC-
raw cells. This is a considerable advantage compared to other sources of stem 
cells, and is pivotal in ensuring the success of future scaling up work as large 
numbers of cells, amounting to approximately 5% of the theoretical liver 
mass, is required for cellular transplantation (Hughes et al., 2012). 
Dissociation and in vitro culture of hAEC-raw cells showed cells with 
diameter averaging 30 µm. These cells demonstrated an epithelial morphology 
in standard maintenance culture, and had a doubling time of 72 hours, 
congurent with literature (Pratama et al., 2011). 
Genotypically, hAEC-raw cells did not express hepatocytic markers 
such as albmin, CYP3A4 and AFP. Immunophenotyping showed that the de 
novo amniotic epithelial layer, from which hAEC-raw cells were isolated, 
were positive for placental and immuno-modulatory marker HLA-G, stem cell 
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marker Oct-4, and epithelial markers E-cadherin and EPCAM. After 
dissociation, majority of hAEC-raw cells also displayed the same 
immunophenotype, indicating that the dissociated cells were consistent with 
the de novo tissue. However, not all cells stained positively for each cell 
surface marker, hence one can argue that hAEC-raw cells did not consist of a 
pure population of cells. 
Glycogen storage, an important liver function, was also investigated 
and hAEC-raw cells showed positive PAS staining. Moore and Persaud 
described that human placental synthesises glycogen as a source of nutrients 
and energy to the fetus (Keith L. Moore, 1998, Takashima et al., 2004). After 
dissociation and culture in vitro, glycogen storage remained in these cells, 
suggesting that hAEC-raw cells shared some hepatocytic function prior to 
hepatic differentiation.  
In conclusion, hAEC-raw cells were easy to derive, expand and 
maintain in culture. In vitro, they retained pluripotency markers and 
immunological markers associated with placental tissue, which we believe sets 
the stage for further in vitro hepatic differentiation. Their epithelial and 
pluripotency markers, as well as their functional ability to store glycogen, akin 
to hepatocytes, suggested that hAECs potentially had a lowered threshold for 
hepatocyte differentiation compared to MSCs, which would require trans-
differentiation whereby efficiency would be lower.  
 
3.5 Limitations 
hAEC-raw cells that could be derived from placental tissues varied 
from 20-50 million cells per sample, and the reason for this variability remains 
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unclear. This could perhaps be attributed to patient age or other comorbidities 
which may affect the placenta.  
In this study, we only tested expansion of hAEC-raw cells up to three 
passages, and observed a slowing down of growth rate. Due to practical 
considerations and availability of large amounts of freshly dissociated hAECs, 
we did not continue to investigate the limit to which hAECs could expand. 
This could be further studied in future. We did not assess the purity of our 
cells, which could be done by fluorescent-activated cell sorting (FACS).  
Also, a telomere length assay can be carried out to assess if telomere 
lengths shorten over time, as this would directly affect senesence of cells and 
its expansion capabilities. In light of future goals for human transplantations, a 
karyotyping analysis should be carried out to ensure that there is no potential 
risks such as genetic transformation with expanded passages.  
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Chapter 4 Hepatic differentiation of hAECs 
4.1 Introduction 
This chapter discusses the in vitro differentiation of hAEC-raw cells 
into hepatocyte-like cells (from here on termed hAEC-hep). Although 
previous groups have shown that undifferentiated hAECs were able to reverse 
animal models of liver fibrosis (Manuelpillai et al., 2012, Manuelpillai et al., 
2010), we hypothesise that hepatic differentiated hAECs would be 
functionally more useful for clinical applications in the reversal of liver 
insufficiency. As part of the effort to translate these cells to clinical care , we 
aimed to devise a method of hepatic differentiation that was efficient (taking 
less than three weeks) and void of animal-derived feeder layers or serum. 
hAEC-hep cells were characterised morphologically, genetically, 
immunophenotypically and functionally. There were concerns that with 
hepatic differentiation, hAECs may lose their immunological markers and thus 
the advantage as immunologically naive cells. As a control, we compared 
hAEC-hep cells to de novo hAEC-raw cells and hAEC cells maintained in 
their epithelial state in maintenance media (from here on termed hAEC-epi). 
hAEC-epi cells were cultured for the same duration as hAEC-hep cells. In 
summary, we compared three types of hAECs in this study: 
1. hAEC-raw - freshly dissociated cells  
2. hAEC-epi- cultured cells in maintenance media  
3. hAEC-hep- hepatic differentiated cells 
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4.2 Materials and methods 
4.2.1 Hepatic differentiation protocol  
The hepatic differentiation protocol described here was adapted from 
Si-Tayeb et al.’s protocol on hepatic differentiation of iPS cells (Si-Tayeb et 
al., 2010). The entire differentiation process took 18 days. Cells were seeded 
on type I collagen coated plates (Advanced BioMatrix), and the culture media 
and its supplements were as follows: 
 






Complete DMEM - Section 3.2.1 
B-27 1x Gibco 
Activin A 100ng/ml PeproTech 
6-10 
Complete DMEM - Section 3.2.1 
B-27 1x Gibco 
 BMP4 20ng/ml Gibco 
FGF-2 10ng/ml BD Biosciences 
11-15 
Complete DMEM - Section 3.2.1 
B-27 1x Gibco 
HGF 20ng/ml Gibco 
16-18 
Hepatocyte culture  
medium (HCM) 
- Lonza 
Oncostatin M 20ng/ml Gibco 
Sodium taurocholate 100uM Sigma-aldrich 
 
4.2.2 Phase contrast microscopy 
Please refer to section 3.2.2 for details. 
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4.2.3 Transmission electron microscopy (TEM) 
After the end of 18 days hepatic differentiation, hAECs were passaged 
using 1x trypsin/EDTA (PAA Co.), and cells in suspension were fixed in 5% 
glutaraldehyde (Sigma-aldrich) overnight at 4°C. Post-fixing was done 
according to standard cell preparation protocol for TEM, and sections were cut 
at 0.1 microns using the Ultracut E Ultramicrotome (Reichert-Jung). Sections 
were then viewed using the JEOL JEM-1010 microscope at 5000x 
magnification. Post-fixing, sectioning and imaging were all performed at the 
NUS Yong Loo Lin School of Medicine Electron Microscopy Unit.   
 
4.2.4 Real-time reverse transcription PCR (RT-PCR) 
Total RNA was isolated from hAECs using standard Trizol method. 
Total RNA was quantified using Nanodrop 1000 spectrophotometer. 100ng of 
RNA was used for reverse transcription to cDNA using the RT2 First Strand 
Kit (Qiagen), following manufacturer’s recommendations. 
RT-PCR was carried out using customised RT2 Profiler PCR array 
plates (Qiagen) according to manufacturer’s protocol. Primer sequences were 
not available as array plates were customized by the company using validated 
primers which are proprietary to them. RT2 SYBR Green ROX qPCR 
Mastermix (Qiagen) was used, and cycling programme was set to a 95°C (10 
minutes), then 40 cycles of 95°C (15 seconds) and 60°C (1 minute). The ABI 
Prism 7000 sequence detection system was used to run the reactions, and 
results were analysed with the RT2 Profiler PCR Array Data Analysis software 
using the ΔΔCT method (version 3.5). 
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Biological triplicates were used in each of the three experimental arms. 
Results represent fold change with respect to hAEC-raw cells.   
 
Table 5 Genes studied in chapter 4. 
Gene Abbreviation 
Alcohol dehydrogenase 1C ADH1C 
Phosphoenolpyruvate carboxykinase PCK1 
Tyrosine aminotransferase TAT 
Glucose-6-phosphatase, catalytic subunit G6PC 
Cytochrome P450 enzymes CYP2D6, CYP2C19, CYP7A1, CYP2C9, CYP2B6, CYP3A4 
Epithelial cell adhesion molecule EPCAM 
CD44 molecule CD44 
Forkhead box A1 FOXA1 
Alpha-fetoprotein AFP 
CCAAT/ enhancer binding protein (C/EBP), 
alpha CEBPA 
Hepatocyte growth factor HGF 
Bone morphogenic protein 4 BMP4 
Nodal homolog NODAL 
Octamer-binding transcription factor 4 Oct-4 
 
4.2.5 Cytospin 
Please refer to section 3.2.6 for details.  
 
4.2.6 Immunofluorescence staining 
Please refer to section 3.2.7 for details. Three non-overlapping fields 
were acquired digitally for each experimental arm, and the mean percentage of 
positively stained cells was calculated. Antibodies used in this section are 
listed as follows:  
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HLA-G Mouse 1:100 1 hour/  Room temperature BD Pharmingen 
HNF-4 Rabbit 1:100 Overnight/ 4°C Abcam 
α1AT Rabbit 1:800 Overnight/ 4°C DAKO 
AFP Mouse 1:100 Overnight/ 4°C Zymed 
Albumin Goat 1:500 Overnight/ 4°C Cappel 
 
4.2.7 Albumin enzyme-linked immunosorbent assay (ELISA) 
To detect human albumin secretion from cultured cells, culture media 
were collected at different time points, and spun at 10,000 rpm for three 
minutes to remove cell debris. Supernatants were stored at -20°C until the day 
of assay.  
Using sandwich ELISA method, a 96 well ELISA plate (Nunc) was 
first coated overnight with 4µg/µl of anti-human albumin antibody (Cappel). 
Bovine serum albumin (BSA) was used as standards, and together with sample 
media, they were loaded into wells the next day and incubated overnight. 
Lastly, 3µg/µl of peroxidase-conjugated anti-human albumin secondary 
antibody (Cappel) was added, and ABTS was used as a substrate to read the 
optical density (405nm) using the Biotek µ Quant Microplate 
Spectrophotometer. Concentrations of albumin in samples were calculated 
using reference from the standard curve established by BSA. Error bars 
represent standard error of n=3 biological samples. 
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4.2.8 CYP inducible enzymatic activity 
CYP2C9 and -3A4 enzymatic activities were detected in vitro using 
P450-Glo CYP2C9 and P450-Glo CYP3A4 Luciferin kits (Promega), 
following manufacturer’s recommendations. Cells were incubated with 
Rifampicin (20µM; Sanofi Aventis) for 72 hours to induce enzymatic 
activities, with daily change of media supplemented with fresh drug. 
Fluorescence intensities were measured using a TECAN GENios fluoremeter, 
and results were reported as the fluorescence fold change of cells before and 
after Rifampicin induction. 
 
4.2.9 Indocyanine green (ICG) uptake and clearance 
Cellular uptake of ICG (MP Biomedicals) was performed using 
1mg/ml ICG in culture media for 1 hour. After which, ICG uptake was 
observed using a phase contrast microscope (section 3.2.2). Cells were then 
rinsed with PBS and returned to fresh culture media without ICG. 6 hours 
later, plates were viewed again to detect ICG clearance from the cell 
cytoplasm.  
 
4.2.10 Low-density lipoprotein (LDL) uptake 
Cultured hAECs were fixed with 4% formaldehyde (ICM Pharma) for 
20 minutes, and incubated with 10µg/ml purified LDL labeled with 1,1’-
dioctadecyl-3,3,3’-tetramethylindo-carbocyanine perchlorate and fluorescent 
probe, Dil, following manufacturer’s instructions (Biomedical Technologies 
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Inc.). Fluorescence was then observed using Olympus Fluoview confocal 
microscope.  
 
4.2.11 Statistical analysis 
All statistical analysis between groups were carried out using Mann-
Whitney nonparametric test, and error bars represent standard error of n=3 
biological samples. Results were considered statistically significant when p < 




4.3.1 hAEC-hep cells showed hepatocyte-like morphology 
When subjected to 18 days of hepatic differentiation, hAEC-hep cells 
proliferated densely and were more polygonal and granular (figure 4.1). Cells 
became closely packed and appeared smaller in size in a time dependent 
manner. 
Electron microscopy showed that hAEC-hep cells accumulated more 
cell organelles including mitochondria and endoplasmic reticulum, compared 
to hAEC-raw and hAEC-epi cells. These were indications of cell maturation 
(figure 4.2). Also, bile canaliculi was observed between neighbouring cells in 
hAEC-hep cells, an important characteristic of mature hepatocytes. This 





Figure 4.1 Hepatic differentiation of hAECs.  
Cell morphology of hAEC-hep culture undergoing 18 days of in vitro 
differentiation (dx). A-F: At day 0, cells displayed epithelial morphology 
before differentiation commenced. Throughout differentiation, cells 
proliferated densely, became polygonal like and were closely packed (phase 




Figure 4.2 In vitro hAEC morphology under phase contrast microscopy 
(A-C) and electron microscopy (D-F).  
A; hAEC-raw cells, before hepatic differentiation, displayed epithelial 
morphology. B: hAEC-epi cells, after 18 days of culture, expanded to 
confluence and maintained its epithelial morphology. C: hAEC-hep, after 18 
days of hepatic differentiation, proliferated to confluence and displayed 
polygonal morphology, typical of liver cells (phase contrast, x10 
magnification). D: hAEC-raw cells in its de novo state showed basic cell 
structures such as nucleus and mitochondria. E: A dividing hAEC-epi cell, 
with basic cell structures but no visible bile canaliculus. F: hAEC-hep cells 
with increased cellular organelles such as endoplasmic reticulum, and bile 
canaliculi between neighbouring cells (blue arrows; transmission electron 
microscopy, x5000 magnification). 
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4.3.2 hAEC-hep cells exhibited elevated liver specific genetic 
markers 
The hepatic genes selected for this study were in reference to a 
proposed standardized method of assessing hepatic-lineage committed cell 
progeny (Sancho-Bru et al., 2009). Transcript levels of genes involved in liver 
functions, CYP450 oxidation, liver development and stem cell characteristics 
were investigated using RT-PCR. All mRNA levels presented were with 
respect to hAEC-raw mRNA levels. 
Liver function genes studied included AHD1C, an enzyme that 
metabolises a wide range of substrates such as ethanol and hydroxysteroids; 
PCK1, the enzyme involved in regulation of gluconeogenesis; TAT, which is 
involved in catalyzation of tyrosine; and G6PC, the final enzyme involved in 
gluconeogenesis and glycogenolysis. AHD1C mRNA levels increased 
significantly by 2.4 fold in hAEC-hep cells, and 5.2 fold in hAEC-epi cells 
(figure 4.3). PCK1 transcript levels was significantly up regulated in hAEC-
hep cells by 3.3 fold. TAT levels also increased significantly by 2.5 fold in 
hAEC-hep cells, and this was significantly higher than levels in hAEC-epi 
cells, which decreased by 0.8 fold. Lastly, G6PC was significantly up 
regulated in hAEC-hep cells by 1.7 fold.  
Among the cytochrome P450 enzymes studied, CYP2D6, -2C19, -2B6 
and -3A4 have the main function of oxidizing xenobiotics. CYP2C9 is 
involved in oxidation of sterioids, fatty acids and drugs, whereas CYP7A1 is 
involved in the cholesterol catabolic pathway. In hAEC-hep cells, CYP2D6, -
2C19 and -7A1 transcript levels increased significantly by 1.4, 2.6 and 4.0 
folds respectively, and -2C9 significantly decreased by 0.6 fold (figure 4.4). 
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CYP7A1 levels were also significantly higher in hAEC-hep than hAEC-epi 
cells (0.9 fold). In hAEC-epi cells, CYP2C19 was significant up regulated by 
6.5 folds, and significantly down regulated by 0.3 fold in CYP2B6. However, 
no significant change was seen in CYP3A4 mRNA levels in both hAEC-hep 
and hAEC-epi cells. 
hAEC-hep cells also showed a significant decrease in liver progenitor 
markers EPCAM and CD44, by 0.3 and 0.4 folds respectively (figure 4.5). 
Liver maturation markers such as FOXA1, AFP and CEBPA and HGF were 
significantly up regulated in hAEC-hep cells by 2.0, 2.3, 7.4 and 3.7 folds 
respectively. Early embryonic development marker BMP4 transcipt level was 
decreased significantly by 0.5 fold. hAEC-epi cells also saw a significant 
decrease in EPCAM levels by 0.1 fold, and BMP4 by 0.2 fold. AFP and 
CEBPA levels were significantly increased by 1.4 and 26.9 folds, and 
transcipt levels were significantly different between hAEC-hep and hAEC-epi 
cells for FOXA1 and CEBPA.  
Stem cell markers NODAL and Oct-4 were both significantly down 
regulated in hAEC-hep cells by 0.5 and 0.3 folds respectively. hAEC-epi cells 





Figure 4.3 RT-PCR analysis of hAEC-epi and hAEC-hep cells I.  
Genes involved in liver function such as ADH1C, PCK1, TAT and G6PC 
were all significantly up regulated in hAEC-hep cells. ADH1C transcript level 
was significantly increased in hAEC-epi cells and TAT levels were 





Figure 4.4 RT-PCR analysis of hAEC-epi and hAEC-hep cells II.  
mRNA levels of cytochrome P450 genes such as CYP2C9, -2D6, -2C19 and -
7A1 were significantly up regulated in hAEC-hep cells. CYP2C19 and -2B6  
levels significantly increased in hAEC-epi cells, and CYP2C19 and CYP7A1 
levels were significantly different between hAEC-epi and hAEC-hep cells 





Figure 4.5 RT-PCR analysis of hAEC-epi and hAEC-hep cells III.  
Transcript levels of liver progenitor markers EPCAM and CD44 were 
significantly down regulated in hAEC-hep cells, and liver maturation markers 
FOXA1, AFP, CEBPA and HGF were significantly up regulated. Early cell 
development marker BMP4 showed significant down regulation hAEC-hep 
cells. EPCAM and BMP4 levels were significantly down regulated in hAEC-
epi cells, but AFP and CEBPA levels were significantly up regulated. FOXA1 
and CEBPA levels were significantly different between hAEC-epi and hAEC-





Figure 4.6 RT-PCR analysis of hAEC-epi and hAEC-hep cells IV.  
Stem cell genes such as NODAL and Oct-4 were significantly down regulated 
in hAEC-hep cells, while only Oct-4 was significantly down regulated in 
hAEC-epi cells (*p<0.05).  
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4.4 hAEC-hep cells displayed liver specific immunophenotype 
Immunofluorescence staining showed that hAEC-hep cells retained 
their placental marker HLA-G, and were positive for hepatic markers such as 
HNF-4, α1AT, AFP and albumin (figures 4.7-4.10). AFP and albumin also 
showed co-localisation within the same cell.  
hAEC-epi cells showed positive staining for HLA-G, AFP and 
albumin. They were weakly positive for HNF-4, and did not show α1AT 
immunophenotype. hAEC-raw cells were negative for all above-mentioned 








Figure 4.7 Immunophenotype of hAEC-epi and hAEC-hep cells I.  
A: hAEC-hep cells were positive for HLA-G protein, even after 18 days of 
hepatic differentiation. hAEC-epi cells also retained its HLA-G 
immunophenotype (epifluorescence, x60 magnification). B: Quantification 
showed no significant difference in HLA-G protein expression between 








Figure 4.8 Immunophenotype of hAEC-epi and hAEC-hep cells II.  
A: After hepatic differentiation, hAEC-hep cells acquired the HNF-4 protein 
expression as seen from positive immunostaining. HNF-4 was also positive in 
some hAEC-epi cells (epifluorescence, x60 magnification). B: Quantification 
showed significantly higher HNF-4 protein expression in hAEC-hep cells 








Figure 4.9 Immunophenotype of hAEC-epi and hAEC-hep cells III.  
A: hAEC-hep cells became positive for α1AT after hepatic differentiation, but 
hAEC-epi cells did no acquire this hepatic characteristic (epifluorescence, x40 
magnification). B: Quantification showed higher protein expression of α1AT 












Figure 4.10 Immunophenotype of hAEC-epi and hAEC-hep cells IV.  
A: Both hAEC-hep and hAEC-epi cells displayed positive staining for AFP 
and albumin, although only hAEC-hep cells showed co-localisation 
(epifluorescence, x60 magnification). B-C: Quantification of both AFP and 
albumin protein expressions showed significantly higher levels for hAEC-hep 
cells, compared to hAEC-epi cells (*p<0.05). 
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4.5 hAEC-hep cells demonstrated liver specific functions 
To confirm that hAEC-hep cells had differentiated into hepatocyte-like 
cells, hepatocyte specific functional tests were performed. 
Human specific albumin was detectable in hAEC-hep cell culture 
supernatant from day three of differentiation onwards, indicating that this liver 
function was only acquired after the commencement of differentiation (figure 
4.11). Albumin secretion peaked at day 18 of differentiation, at 3640pg/ml, 
and no albumin secretion was detected in hAEC-epi cells (results not shown). 
To detect inducible cytochrome P450 enzymatic activities, we 
compared luciferase fluorescence intensities before and after rifampicin 
incubation. hAEC-hep cells demonstrated the highest CYP2C9 fold change at 
2.1 fold increase, which was significantly higher than the change seen in 
hAEC-epi cells (0.7 fold; figure 4.12). Control cells, human fetal hepatocytes 
(HFH), only showed a fold change of 1.5 times, and this was also significantly 
different from the fold change seen in hAEC-epi cells. However, no statistical 
difference was found between HFH and hAEC-hep cells CYP2C9 inducible 
activities. In CYP3A4, hAEC-hep cells also showed highest fold change at 2.5 
fold increase, and this was significantly higher than the change seen in hAEC-
epi cells (0.6 fold) and HFH (1.4 fold). Statistically significant difference was 
also found between hAEC-epi cells and HFH.  
When incubated with ICG, up to 5% of hAEC-hep cells demonstrated 
ICG uptake, which was then eliminated from the cytoplasm 6 hours after they 
were returned to standard culture media without ICG (figure 4.13). Only 
minimal uptake and clearance was seen in hAEC-epi cells.  
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hAEC-hep cells also acquired the ability to uptake LDL in a 





Figure 4.11 Albumin secretion by hAEC-hep cells in vitro.  
ELISA revealed that albumin secretion by hAEC-hep cells only started after 
hepatic differentiation protocol was initiated. Albumin levels peaked at day 18 
of differentiation. No albumin secretion was detected in hAEC-epi cells 







Figure 4.12 Inducible CYP2C9 and CYP3A4 enzymatic activities.  
The results represent the fold change between luciferase fluorescent 
absorbance before and after rifampicin incubation. hAEC-hep cells exhibited a 
2.1 fold increase in CYP2C9 inducible activity, significantly higher than the 
change seen in hAEC-epi cells. hAEC-hep cells also showed a 2.5 fold 
increase in CYP3A4 inducible activities, which was also significantly higher 





Figure 4.13 ICG uptake and clearance in hAEC-epi and hAEC-hep cells.  
hAEC-epi cells exhibited minimal ICG uptake and clearance (red arrows), 
whereas hAEC-hep cells showed more ICG uptake, and its successful 





Figure 4.14 LDL uptake in hAEC-hep cells.  
Minimal LDL uptake was seen in hAEC-epi cells, indicated by weak LDL 
signal (red fluorescence). More LDL uptake was detected in hAEC-hep cells 
(confocal, x10 magnification). Overlay pictures on the right panel comprised 
of corresponding fluorescence and phase contrast images.  
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4.6 Interpretation and conclusion 
In this chapter, we sought to assess the effectiveness of our 
differentiation protocol and validate the quality of hAEC-hep cells.  
Akin to iPSCs, hAECs were primitive and plastic in nature, hence we 
adapted our differentiation protocol from the iPSC hepatic differentiation 
method published by Si-Tayeb et al (Si-Tayeb et al., 2010). This protocol used 
a four-step process that mimicked the natural process of hepatic 
differentiation, and was free of animal feeder layers. The main difference in 
our adapted protocol was the shorter duration (18 days instead of 20 days), 
and the addition of bile salt, sodium taurocholate, for the last three days of 
differentiation.  
Based on albumin immunofluorescence staining, we observed a 30-
50% efficiency in hepatic differentiation of hAECs in vitro. When subjected to 
18 days of hepatic differentiation, hAEC-hep cells exhibited proliferative 
properties and became more polygonal and granular, similar to the 
morphology of hepatocytes. Electron microscopy revealed that hAEC-hep 
cells became more mature with more cell organelles, and displayed the 
presence of bile canaliculi, typical of a mature hepatocyte.  
On a transcript level, liver function genes demonstrated statistically 
significant up regulations in hAEC-hep cells with an increase of more than 2 
folds in ADH1C, PCK1 and TAT, but only 1.67 fold in G6PC. Among the 
CYP450 genes studied, hAEC-hep cells displayed the most prominent 
increase in transcipt levels for CYP7A1 (4.0 folds) and CYP2C19 (2.6 folds). 
Notably, the increase in CYP7A1 levels resembled the natural condition seen 
in fetal livers. However, other cytochrome P450 enzymes studied showed only 
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slight increases in transcipt levels, and no significant change was detected in 
the most important CYP3A4 enzyme.  
hAEC-hep cells also demonstrated significant decrease in liver 
progenitor markers, EPCAM and CD44, early embryonic development marker 
BMP4, and stem cell markers NODAL and Oct-4. This showed that hAEC-
hep cells were maturing from its primitive fetal state. Early hepatoblast gene 
AFP, and late fetal postnatal hepatocyte genes FOXA1, CEBPA and HGF 
were all significantly up regulated in hAEC-hep cells, indicating that hAECs 
were differentiating and becoming hepatocyte-like.  
Immunostaining reveled that hAEC-hep cells retained the HLA-G 
protein signature, which plays an important role in immunomodulation and 
also subsequent cell tracing in animal studies. HNF-4, α1AT, AFP and 
albumin were also positive in hAEC-hep cells.  
We also characterised the functional capabilities of hAEC-hep cells. 
They secreted albumin, exhibited inducible CYP2C9 and CYP3A4 activities, 
were able to uptake and clear ICG, and uptake LDL. Although no increase in 
CYP2C9 and -3A4 was seen on the genetic level, acquiring inducible 
enzymatic activites were an indication of successful hepatic differentiation in 
hAEC-hep cells. 
All in all, we concluded that our differentiation protocol was effective 
in guiding hAECs to express hepatocyte specification factors, start 
differentiation, and acquire some hepatocytic functions. The gold standard of a 
fully functional hepatocyte is defined by its metabolic functions. In our hands, 
we were able to turn on the liver specification genes and demonstrated liver 
functions specific for hepatocytes. However, hAEC-hep cells displayed a more 
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primitive hepatic genetic signature, closer to that of liver progenitor cells in 
early differentiation rather than mature adult liver cells. Our in vitro 
differentiation initiated the genetic alteration of hAECs into a “hepatocytic” 
lineage, but was not very effective in differentiating them into mature 
hepatocytes with a full panel of hepatocytic functions. Nonetheless, we 
believe that these cells were primed for the liver lineage, and sought to explore 
if the liver injury environment in an animal model will be able to drive our 
cells into differentiation. 
Also, the efficiency of differentiation was not very high. This raises the 
possibility that despite the perceived homogenous population of cells, hAECS 
may still have a mixed population with different plasticity. Further work using 
FACS to identify the subpopulation with highest efficiency will be useful.  
 
4.7 Limitations 
In this study, we acknowledge that the effectiveness of hepatic 
differentiation of hAECs were not as superlative as we had hoped for it to be. 
Although hAEC-hep cells did display features classically thought to be that of 
hepatocytes, we were not able to improve their differentiation efficiency 
despite efforts to optimise our protocol. This also highlights the difficulty that 
many face in in vitro hepatocyte cultures. 
We were not able to fully recapitulate the liver environment on a 2D 
culture system in vitro, be it in terms of liver architecture or the complex 
cross-talk amongst various cells types of the liver. This limitation could be 
addressed in future studies, such as introducing a 3D culture system using 
matrigel or carbon nanotubes, and culturing different types of liver cells (such 
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as liver sinusoidal endothelial cells, bile duct cells etc) together to establish 
cellular polarity and enhance differentiation. Also, it would be worthwhile to 
investigate the metabolic profile of hAEC-hep cells in future.  
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Chapter 5 Xenotransplantation of hAECs 
5.1 Introduction 
Given the limitations in in vitro differentiation of hepatocytes, we 
tested if the in vivo environnment of liver injury may be able to push our cells 
into functional hepatocytes. We transplanted hAEC-raw, hAEC-epi and 
hAEC-hep cells into immunopermissive mice to investigate their in vivo 
efficacy. Human adult hepatocytes were also transplanted as a benchmark for 
comparison. Immuno-compromised NOD scid gamma (NSG) mice were 
treated with thioacetamide to induce chronic liver failure, and these cells were 
transplanted intra-splenically into individual animals.  
We aimed to assess and compare if these cells could engraft and 
survive successfully into the mouse liver parenchyma, improve serum markers 
of liver injury, and improve the state of fibrosis. We also transplanted hAEC-
epi cells into immuno-competent C57BL/6 mice as a pilot study to examine if 
these cells could evade host immunity and show engraftment.  
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5.2 Materials and methods 
5.2.1 Animals 
Two strains of mice were used in this study- NSG mice and C57BL/6 
mice. NSG mice were purchased from The Jackson Laboratory, and C57BL/6 
mice from the Animal Holding Unit (AHU) of the National University of 
Singapore (NUS). All animals were housed in AHU, and all procedures 
obtained Institutional Animal Care and Use Committee (IACUC) approval 
prior to commencement of work. NSG mice are immunodeficient, lacking in 
mature B and T cells, functional NK cells and deficient in cytokine signalling 
(Shultz et al., 2005). C57BL/6 mice are a immunocompetent strain.  
 
5.2.2 Induction of chronic liver failure  
Chronic liver injury was induced in NSG mice using thioacetamide 
(TA) as the injury agent. 200µg/L of TA was dissolved into mouse drinking 
water, and fibrosis was achieved after four months of TA administration. This 
method was developed in-house by Dr Zhou Lei and Dr Mark Muthiah (data 
not published yet).  
 
5.2.3 Xenotransplantation of cells into mice 
Five arms of transplantations were involved in this study, namely: 
1. PBS sham-injection 
2. hAEC-raw cells 
3. hAEC-epi cells 
4. hAEC-hep cells 
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5. Human adult hepatocytes 
After NSG mice were fed TA for 4-5 months, 2  106 cells suspended 
in 200µl PBS were transplanted into individual mice intra-splenically. 
Negative control animals were transplanted 200µl PBS without any cells. 
Three animals were used in each experimental arm, and animals were 
sacrificed one-month after transplantation. TA administration continued after 
cellular transplantation until the day of sacrifice.  
Human adult hepatocytes were isolated from consenting patients with 
HCC who underwent liver transplantation in NUH. Normal liver tissue were 
cut from the non-cancerous area, and cells were isolated using 3mg/ml 
Collagenase A (Roche). Dissociated cells were immediately transplanted into 
animals.  
 
5.2.4 Immunofluorescence/ Immunohistochemical staining 
Please refer to section 3.2.7 for details on immunofluorescence (IF) 
staining.  
For immunohistochemical (IHC) staining, method was identical to that 
described in section 3.2.7 up to the primary antibody step. Subsequently, 
slides were incubated with secondary antibodies conjugated with horseradish 
peroxidase (Roche) for one hour at room temperature, before adding substrate 
3,3’-diaminobenzide (DAB; Sigma-aldrich). Slides were then dehydrated 
using 70%, 90% and 100% ethanol in sequential changes, followed by three 
xylene changes, and countertained with Mayer’s hematoxylin (Sigma-aldrich).   
Antibodies used in this section are listed as follows:  
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Table 7 List of antibodies used in chapter 5. 








Albumin Goat 1:500 Overnight/ 4°C Cappel 
HLA-G Mouse 1:100 
1 hour/  
Room temperature 
BD Pharmingen 
     
Anti-mouse 
 αSMA Rabbit 1:100 
1 hour/  
Room temperature 
Abcam 









5.2.5 Sirius red staining and quantification using ImageJ 
To assess fibrosis, mouse liver sections were incubated with 0.1% 
wt/vol Picrosirius Red (Fluka) that stained for collagen fibres. Three non-
overlapping fields were acquired digitally for each animal in all arms of the 
animal experiment. Area of fibrosis was quantified as percentage of red-
stained area by computer-assisted morphometry using ImageJ 1.4.6r 
programme. The same quantification method was also used quantify αSMA 
positive cells.  
 
5.2.6 Mouse serum analysis 
Analysis of mouse serum makers of liver injury such as albumin, total 
bilirubin, alanine transaminase (ALT) and aspartate transaminase (AST) were 
done as a service at the NUS Veterinary Diagnostic Laboratory. Prothrombin 
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time was measured using CoaguChek XS PT test strips (Roche), and results 
were represented as international normalized ratio (INR).   
 
5.2.7 Cell rejection study 
To investigate if hAEC-epi cells could engraft into the liver of a 
immuno-competent animal, 2 million hAEC-epi cells were transplanted intra-
splenically into 12 week old C57BL/6 mice. Three animals were used.  
Before transplantaion, hAEC-epi cells were stained with Vybrant dye 
(Invitrogen) according to manufacturer’s recommendations, and this enabled 
in vivo cell tracing. Animals were sacrificed one month after transplantaion, 
and immunofluorescence was performed on liver sections to detect cell 
engraftment.  
 
5.2.8 Statistical analysis 




5.3.1 Establishment of chronic liver injury model 
Current animal models of liver cirrhosis, such as using CCl4 as a toxic 
agent, are mainly fibrotic models which do not represent the full picture of a 
decompensated liver. Clinical correlates of cirrhosis, such as synthetic 
function (serum albumin), excretory fucntion (serum total bilirubin) and 
coagulopathy (prothrombin time) have yet to be recapitualted in mouse 
models that are currently available. 
As such, a new, immuno-permissive mouse model of liver cirrhosis 
was developed in our lab, led by Drs. Zhou Lei and Mark Muthiah 
(publication in preparation). Thioacetamide (TA), a hepatotoxin which yields 
a toxic metabolite after CYP450 enzymatic metabolism, causes widespread 
free radical mediated lipid peroxidation and will lead to liver cirrhosis (Bruck 
et al., 1999, Kadir et al., 2013, Kadir et al., 2011, Spira and Raw, 2000). This 
model has been well established in rats, but have yet to be described 
comprehensively in mice.  
After 4 months of TA administration into NSG mice, mouse livers 
became evidently more nodular and hard; sirius red staining revealed the 
presence of more collagen fibers compared to control animals which did not 
receive TA (figure 5.1). Serum albumin levels decreased significantly from 
21.5g/L in control mice to 3.6g/L, and serum total bilirubin levels increased 
significantly from 0.4mg/dL to 2.3mg/dL. Prothrombin time, represented by 
INR, also worsened significantly after TA administration.  
In short, our lab has established a animal model of liver cirrhosis that 
presented not only with extensive fibrosis but also clinical correlates of liver 
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decompensation. This animal model was used for hAEC transplantation in 
subsequent studies.   
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Figure 5.1 Liver macro-morphology, fibrosis and clinical correlates of 
chronic liver injury in NSG mice.  
After 4 months of TA administration, livers of NSG mice presented with large 
nodules and were hardened. Sirius red staining (phase contrast, x10 
magnification) showed extensive fibrosis, and clinical correlates of liver 
disease such as serum albumin, total bilirubin and prothrombin time were 
significantly more severe after TA administration (*p<0.05). Photo credit: Dr. 
Zhou Lei.   
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5.3.2 hAEC transplantation improved macro-morphology of 
mouse livers 
Gross liver morphology of control mice transplanted with PBS 
displayed numerous large nodules, was hard in texture, and also appeared 
shrunken in size (figure 5.2). Comparatively, livers of animals transplanted 
with hAEC-raw, hAEC-epi or hAEC-hep cells were larger, did not show any 




Figure 5.2 Macro-morphology of mouse livers transplanted with various 
hAEC cell types.  
External liver morphology showed a shrunken state with numerous nodules in 
liver of control animals transplanted with PBS. Animals transplanted with 
hAEC-raw, hAEC-epi and hAEC-hep cells all showed improved morphology, 
with no large nodules present and less shrunken. 
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5.3.3 Survival of hAECs in mouse livers one month post-transplant 
To investigate if hAECs have successful engrafted in the mouse livers, 
we used human specific immunolabelling for human-HLA-G and human-
albumin. In animals transplanted with hAEC-raw, hAEC-epi or hAEC-hep 
cells, livers all showed positive human-HLA-G and albumin immunostaining, 
indicating successful engraftment and preservation of their 
immunomodulatory properties in vivo (figures 5.3-5.4). These cells also co-






Figure 5.3 Human specific immunophenotype of mouse livers 
transplanted with PBS and hAEC-raw cells.  
Control animals transplanted with PBS showed negative staining for human 
specific HLA-G and albumin in the livers. Animals transplanted with hAEC-
raw cells showed positive co-labeling of human HLA-G and albumin, 
indicating that they were functioning as a hepatocyte-like cell and also had 






Figure 5.4 Human specific immunophenotype of mouse livers 
transplanted with hAEC-epi and hAEC-hep cells.  
Animals transplanted with both hAEC-epi and hAEC-hep cells displayed 
positive co-labeling of human HLA-G and albumin, similar to animals 
transplanted with hAEC-raw cells (epifluorescence, x40 magnification).  
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5.3.4 Reduction in fibrosis after transplantation of hAECs 
hAECs have been reported to have anti-fibrotic effects. To determine if 
our differentiated cells retained this capability, we transplanted and compared 
the different types of hAECs in vivo. 
To assess if fibrosis decreased after hAEC tranplantation, sirius red 
staining was employed to identify collagen fibres within the mouse liver 
parenchyma. Staining showed defined fibrosis in control animals and animals 
transplanted with human adult hepatocytes, but fibrosis was less severe in 
animals transplanted with either three types of hAECs (figure 5.5). 
Quantification of percentage red areas in these images revealed a significant 
reduction in collagen fibres in animals transplanted with hAEC-raw (1.0%), 
hAEC-epi (1.8%) and hAEC-hep cells (1.3%), compared to control animals 
(3.9%) and adult-hepatocyte transplanted animals (3.4%). hAEC-raw and 
hAEC-hep cells also showed significantly lower amounts of fibrous tissues in 
mouse livers compared to hAEC-epi cells.  
Activated myofibroblasts, the main cell type that deposits collagen 
during the liver reparative process, is αSMA positive, and this marker was 
used to investigate if the amount of activated myofibroblasts corresponded to a 
similar trend seen in sirius red staining. Quantification of percentage of αSMA 
positive areas showed a significant reduction after transplantation with hAEC-
raw (0.8%), hAEC-epi (0.3%) and hAEC-hep cells (0.7%) compared to 
control animals (1.8%) and adult hepatocyte transplanted animals (1.6%). This 
corroborated the results from sirius red staining, and showed a close 
relationship between reduction of fibrosis and reduction in activated 




Figure 5.5 State of fibrosis in transplanted animals.  
As seen from the sirius red staining, defined fibrosis was seen in control 
animals transplanted with PBS, and animals transplanted with human adult 
hepatocytes. Fibrosis marked decreased after transplantation with hAEC-raw, 
hAEC-epi and hAEC-hep cells (phase contrast, x10 magnification). 
Quantification of percentage red-stained areas in images showed a significant 
decrease in fibrous tissue after transplantation with either three types of 
hAECs, compared to control animals. Transplantation with adult hepatocytes 
did not decrease fibrosis, and was significantly higher than hAEC transplanted 
animals. Transplantation with hAEC-raw and hAEC-hep cells also reduced 





Figure 5.6 Quantification of αSMA cells in transplanted animals.  
Reduction in αSMA positive activated myofibroblasts followed a similar trend 
as sirius red staining (phase contrast, x10 magnification). Quantification of the 
percentage of αSMA positive cells showed highest amounts in control animals 
transplanted with PBS, and significant reductions were seen after 
transplantation with either three types of hAECs. Adult hepatocyte 
transplantation did not show a reduction in αSMA positive cells, and was 
significantly higher than hAEC transplanted counterparts. hAEC-raw cell 
transplantation also resulted in a significantly lower percentage of αSMA 
positive cells compared to hAEC-epi cell transplantation (*p<0.05). 
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5.3.5 Improvements in mouse serum markers of liver injury after 
transplantation with hAECs 
To investigate if chronic liver injury was attenuated, mouse serum 
markers of liver injury were measured.  
Mouse liver synthetic function were assess by serum albumin, total 
bilirubin and PT. Serum albumin levels increased significantly after 
transplantation with hAEC-epi cells (12.8g/L), hAEC-hep cells (8.9g/L) and 
adult hepatocytes (27.5g/L), compared to control animals (4.6g/L). No change 
was seen after hAEC-raw cell transplantation. Adult hepatocyte 
transplantation also resulted in higher serum albumin levels in mice compared 
to transplantation of all three types of hAECs (figure 5.7). Serum total 
bilirubin saw significantly fell only after transplantation with hAEC-hep cells 
(0.8mg/dL) and adult hepatocytes (0.2mg/dL), compared to control animals 
(2.3mg/dL). No reduction was seen in animals transplanted with hAEC-epi or 
hAEC-hep cells. Adult hepatocyte transplantation also resulted in total 
bilirubin levels that were significantly lower than transplantation of all three 
types of hAECs. PT, represented by INR, was significantly reduced after 
transplantation of all cell types, compared to control animals (figure 5.8).  
Liver cellular injury was investigated using serum ALT and AST 
levels. Serum ALT levels were only significantly lower in hAEC-hep cell 
transplantation (85.37U/L), compared to adult hepatocyte transplantation 
(212.7U/L). No significant difference was detected between control and cell 
transplanted animals (figure 5.9). Serum ALT levels were significantly higher 
in animals transplanted with hAEC-raw cells (375.5U/L) compared to control 
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animals (230.6U/L) and hAEC-hep cell transplanted animals (164.4U/L). No 




Figure 5.7 Mouse serum markers of liver injury I.  
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Mouse serum albumin levels significantly increased after transplantation with 
hAEC-epi and hAEC-hep cells, compared to control animals. However, serum 
albumin levels of animals transplanted with either three types of hAECs were 
significantly lower than animals transplanted with human adult hepatocytes. 
Mouse serum total bilirubin levels significantly decreased only after 
transplantation with hAEC-hep cells and adult hepatocytes, and adult 
hepatocytes yielded significantly lower levels compared to all other types of 
transplantation. hAEC-hep cell transplantation also resulted in significantly 







Figure 5.8 Mouse serum markers of liver injury II.  
Prothrombin time, represented by INR, significantly decreased after 





Figure 5.9 Mouse serum markers of liver injury III.  
Mouse serum ALT levels did not alter significantly after hAEC 
transplantations compared to control animals, but hAEC-hep cell 
transplantations resulted in significantly lower ALT levels compared to adult 
hepatocyte transplantation. Mouse serum AST levels significantly increased 
after hAEC-raw cell transplantation compared to control animals and hAEC-
hep cell transplanted animals (*p<0.05).  
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5.3.6 hAEC-epi cells engrafted in C57BL/6 mouse livers 
As a pilot study, hAEC-epi cells were transplanted into C57BL/6 
immuno-competent animals to determine if these cells could evade host 
immunity and engraft into the mouse livers. As hAEC-epi showed similar 
HLA-G immunophenotype with hAEC-raw and hAEC-hep cells, we chose to 
transplant this cell type. Cells were also stained with Vybrant dye prior to 
transplantation. 
Immunofluorescence staining revealed that HLA-G and fluorescein 
positive cells were present in the mouse liver parenchyma of C57BL/6 mice, 
indicative that hAEC-epi cells have evaded rejection and engrafted (figure 
5.10). This was also congruent to data shown by Manuelpillai et al. 




Figure 5.10 Immunofluorescence detection of hAEC-epi cells transplanted 
into C57BL/6 mice.  
Immunofluorescence staining showed that hAEC-epi cells engrafted into the 
livers of C57BL/6 immuno-competent animals. Cells were stained with 
Vybrant dye before transplantation, hence the detection of fluorescein 
(epifluorescence, x40 magnification).  
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5.4 Interpretation and conclusion 
In order to test the therapeutic efficacy of hAEC derived hepatocyte-
like cells, we transplanted 2 million hAEC-raw, hAEC-epi or hAEC-hep cells 
into individual NSG mice with chronic liver injury. PBS was transplanted into 
animals as a negative control, and human adult hepatocytes were transplanted 
as a benchmark for comparison of the quality of hAECs in vivo. 
One month post-transplantation, all three types of hAEC cells 
markedly improved gross morphology of mouse liver tissues, with little to no 
nodules found on the surfaces, with little shrinkage in liver size. 
Immunofluorescence experiments also confirmed the engraftment of these 
hAECs in the mouse liver parenchyma with an efficiency of 1-2%, which was 
consistent with previous reports (Gupta et al., 1999). They were also human 
HLA-G and albumin positive, indicating that they retained their immuno-
modulatory and hepatocyte-like properties. Detection of human-albumin 
positive cells after hAEC-raw transplantation also suggested that hAECs could 
spontaneously differentiate into hepatocyte-like cells in vivo under injury 
stimulus.  
Using sirius red staining, we found significant reduction in fibrosis in 
animals that were transplanted with either three types of hAECs. Interestingly, 
no reduction was seen in animals transplanted with adult hepatocytes. This 
was directly correlated to αSMA immunostaining, which also presented a 
similar trend of reduction. This suggest that fibrosis reversal seen was due to 
non-parenchymal effects of hAECs and their lineages rather than their direct 
contribution to the hepatocye fraction.  
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Serum markers of injury were measured to investigate if hAECs had an 
ameliorative effect on chronic liver failure. Liver function marker, serum 
albumin, showed significant improvements after transplantation with hAEC-
epi and hAEC-hep cells, but not hAEC-raw cells. However, these 
improvements were not comparable to that effected by human adult 
hepatocyte transplantation, which was significantly higher. Serum total 
bilirubin levels saw a significant reduction after transplantation of hAEC-hep 
cells and human adult hepatocytes, but improvements caused by hAEC-hep 
cells were also significantly lesser than that caused by adult hepatocytes. 
Prothrombin time saw a significant decrease across transplantation of all cell 
types.  
Liver cellular injury was studied through ALT and AST serum levels, 
and no meaningful results were obtained from transplantations of all cell 
types. Interestingly, adult hepatocyte transplantation saw a spike in the serum 
ALT and AST levels, instead of a decrease.  
In light of future therapeutic applications of hAECs, we also 
transplanted hAEC-epi cells into immuno-competent C57BL/6 mice to 
investigate if these cells coulld evade host immunity and engraft successfully. 
Manuelpillai et al. had previously reported engraftment of freshly dissociated 
hAECs in C57BL/6  mouse liver, and here we have shown that hAEC-epi 
cells, which have been kept in culture for 18 days, still retained their 
immunomodulatory properties and was able to engraft in the liver of a foreign 
organism.  
Between hAEC-raw, hAEC-epi and hAEC-hep cell transplantations, 
no significant difference was seen in terms of improvements in liver macro-
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morphology, survival and engraftment, reduction in liver fibrosis and 
coagulopathy (PT). However, only hAEC-epi and hAEC-hep cell 
transplantations demonstrated significant improvements in liver synthetic 
function (serum albumin levels), and only hAEC-hep cell transplantation 
showed significant improvement in liver excretory function (serum total 
bilirubin levels). Therefore, transplantation of hAEC-hep cells exhibited the 
best improvement in clinical correlates of chronic liver failure, but 
interestingly, all three hAEC cell types had comparable anti-fibrotic effects.  
This suggest that the therapeutic effect of hAECs on cirrhotic liver was 
multi-faceted. In vitro epithelial culture and hepatocytye differentiation 
improved mouse hepatocytic synthetic and excretory functions, although 
highest effect was seen when transplanting adult hepatocyte. However, while 
adult hepatocyte could contribute to hepatocytic functions, it was the amniotic 
based cells that had the capacity to reverse fibrosis. 
In summary, hAECs had shown great efficacy in the treatment of 
chronic liver injury. Although serum injury markers showed that hAECs have 
not reached therapeutic potential comparable to human adult hepatocytes, they 
have exhibited the ability to regress fibrosis which was not seen in adult 
hepatocytes. This was a unique feature of hAECs, and their mechanism of 
action is explored in the next chapter. 
 
5.5 Limitations 
After 4 months of TA administration, some animals became very sick 
with evidence of ascites and jaundice. One difficulty we faced was that some 
animals could not survive transplantation and died during the procedure. This 
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phenomenon was observed regardless of the type of cell transplanted, 
indicating that it was independent of cellular transplantation. Also, these mice 
were extremely sensitive to anesthesia, hence anesthesia levels had to be 
titrated and reduced to the lowest to ensure the survival of mice after 
transplantation. This, however, was a true reflection of high mortality and 
morbidity of liver cirrhosis. While transplantation at earlier time points may 
have bypassed this problem and demonstated survival advantage, the ability of 
fibrosis reversal in advanced cirrhosis with cell transplantion reflected the 
robustness of this therapeutic intervention.   
Also, studies on the long term effects of hAECs could be carried out. 
Would hAECs continue to reverse fibrosis? Would they still survive and 
continue to exert positive effects on livers with chronic injury after 6-9 
months? Would it be meaningful to transplant repeated doses of hAECs, and 
how long should each transplantation be spaced out? These are important 
questions to be answered in future.  
It would also be worthwhile to isolate the transplanted cells for further 
evaluation of their hepatocytic functions. Mouse livers could be perfused, and 
hAECs could be isolated using FACS, probing for human specific HLA-G. 
This would shed light on the extent of hepatic differentiation that hAECs are 
capable of.  
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Chapter 6 Mechanism of action for in vivo fibrosis regression 
6.1 Introduction 
In the previous chapter, we described that hAECs were able to reduce 
the state of fibrosis and improve chronic liver injury of mouse livers in vivo. 
Here, we seek to understand the mechanism of this fibrosis regression. 
Hepatic fibrosis, which was long deemed to be irreversible, is now 
proven to be otherwise. Fibrosis, which is a highly dynamic process, involves 
many players and a tip in their equilibrium would result in either fibrosis 
progression or regression.  
In this chapter, we explored various well established mechanisms of 
fibrosis regression (reviewed in section 2.1.2), and explored how hAECs may 
have resulted  in the reduction of fibrosis. In chapter 5, we saw that 
transplantation with adult hepatocytes did not result in fibrosis regression, and 
this suggests that the antifibrotic effect was due to intrinsic non-parenchymal 
effect of hAECs. The anti-fibrotic effect of hAEC-raw cells have been 
reported in literature in organs including the lung and liver (Manuelpillai et 
al., 2012, Manuelpillai et al., 2010, Moodley et al., 2010), but never in hAEC-
hep cells.  
The proposed mechanisms include:  
1. Reduction in oxidative stress caused by thioacetamide-induced 
chronic liver failure. 
2. In vivo differentiation of hAECs into liver sinusoidal 
endothelial cells (LSECs), thereby promoting quiescence or 
apoptosis of activated myofibroblasts.  
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3. Activation of anti-inflammatory macrophages and increase in 
MMPs.  
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6.2 Materials and methods 
6.2.1 Thiobarbituric Acid Reactive Substances (TBARS) assay 
Oxidative stress was measured using the TBARS assay kit (Cayman 
Chemical Company), according to manufacturer’s recommendations. This kit 
measures malondialdehyde (MDA), which is a naturally occurring product of 
lipid peroxidation, and lipid peroxidation is a mechanism of cellular damage 
caused by oxidative stress. Results were measured fluorometrically; a higher 
fluorometric intensity was indicative of more oxidative stress. The dynamic 
range of the assay was stated to be between 0 – 50 µM MDA equivalents. 
 
6.2.2 Immunofluorescence staining 
Please refer to section 3.2.7 for details. Three non-overlapping fields 
were acquired digitally for each experimental arm, and the mean percentage of 
positively stained cells was calculated. Antibodies used in this section are 
listed as follows:  
 














1 hour/  
Room temperature 
R&D systems 
HLA-G Mouse 1:100 
1 hour/  
Room temperature 
BD Pharmingen 
Albumin Goat 1:500 Overnight/ 4°C Cappel 
CD31 Mouse 1:20 
1 hour/  
Room temperature 
DAKO 
Desmin Rabbit 1:50 




6.2.3 hAEC- LX-2 co-culture system 
LX-2 cells, an activated myofibroblast cell line, were obtained from Dr 
Xie Min of National Cancer Centre Singapore as a gift. LX-2 cells were 
seeded on petri dishes, and hAEC-raw, hAEC-epi and hAEC-hep cells were 
cultured on separate transwell membrane inserts. LX-2 cells and various 
hAECs were co-cultured for 3 days, afterwhich LX-2 cells were passaged, 
cytospun onto glass slides, and fixed in acetone for downstream experiments. 
 
6.2.4 Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay 
Apoptosis was measured using the APO-BrdU TUNEL assaay kit 
(Invitrogen), according to the manufacturer’s recommendations. Fluorescence 
was detected using a Olympus BX60 epifluorescence microscope. 
 
6.2.5 RT-PCR 
RNA isolation method, cDNA syntheis, cycling conditions and data 
analysis were identical to that described in section 4.2.4. However, genes 
studied in this chapter were not part of the RT2 Profiler PCR array plates. 
Primers used were purchased from AITbiotech, and details are listed below. 
Biological triplicates were used in each of the three experimental arms. 
Results represent fold change with respect to hAEC-raw cells.  
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Table 9 Primers used in chapter 6. 

















































6.2.6 Statistical analysis 
Please refer to section 4.2.11 for details.   
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6.3 Results 
6.3.1 Fibrosis regression was not associated with a reduction in 
oxidative stress 
During 4 months of TA administration, this hepatotoxin induces 
widespread free radical mediated lipid peroxidation (Bruck et al., 1999, Kadir 
et al., 2013, Kadir et al., 2011, Spira and Raw, 2000). Hence, we sought to 
examine if hAEC transplantation resulted in a reduction in the oxidative stress 
caused by TA, hence removing the injury stimulus.  
TBARS assay was carried out to assess the amount of MDA produced 
by lipid peroxidation, an indicator of cellular injury caused by oxidative stress. 
Results showed no significant difference between control mouse livers and 
those transplanted with either three types of hAECs (figure 6.1). Hence, a 
reduction in liver oxidative stress was not likely the mechanism of action for 





Figure 6.1 TBARS assay for oxidative stress.  
No significant change in oxidative stress was found between mouse livers of 
animals transplanted with either three types of hAECs.  
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6.3.2 In vivo differentiation of hAECs into LSECs 
Xie et al. and Deleve et al. had reported that restoration of fenestrated 
LSECs can cause fibrosis regression in the liver (Deleve et al., 2008, Xie et 
al., 2012). In order to test if hAECs were indeed contributing to the LSEC 
pool, we performed immunostaining to probe for LSECs with human origin 
using human-specific KDR and CD31 antibodies. 
Immuno-fluorescence staining revealed that both KDR and CD31 were 
found in livers of animals transplanted with either three types of hAECs, 
indicating that hAECs were differentiating into LSECs in the in vivo 
environment of chronic liver failure (figures 6.2-6.5). These cells were also 
co-labeled with human HLA-G and albumin, indicating their specificity. 
However, we were unable to quantify the proportion of hAEC-derived LSECs 
as the cells were too small for detection by ImageJ software; this was a 




Figure 6.2 In vivo detection of human-derived LSECs in transplanted 
livers I.  
Immunofluorescence staining revealed that human KDR and HLA-G positive 





Figure 6.3 In vivo detection of human-derived LSECs in transplanted 
livers II. 
Immunofluorescence staining revealed that human KDR and HLA-G positive 
cells were also detected in mice transplanted with hAEC-epi and hAEC-hep 





Figure 6.4 In vivo detection of human-derived LSECs in transplanted 
livers III. 
Human specific albumin and CD31 cells were detected in livers of animals 




Figure 6.5 In vivo detection of human-derived LSECs in transplanted 
livers IV. 
Human specific albumin and CD31 cells were also detected in livers of 




6.3.3 Did hAECs differentiate into LSECs in vitro? 
Retrospectively, we went back to investigate if hAECs were becoming 
endothelial like cells in vitro. Immnostaining of KDR and CD31 revealed that 
hAEC-raw and hAEC-epi cells were negative for both markers (results not 
shown), but hAEC-hep cells were KDR positive and CD31 negative. This 
suggested that hAEC-hep cells were becoming a subset of pre-hepatic cells as 
described by Goldman et al. (Goldman et al., 2013), but not yet a LSEC. 
However, in vivo, hAECs were able to differentiate into KDR and CD31 
positive LSEC-like cells, and this mechanism remains unclear. This also 
suggests that hAEC-hep cells derived from in vitro hepatic differentiation had 
bi-potential properties and given the right stimulus in vivo, could differentiate 
into KDR and CD31 positive LSECs. 
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Figure 6.6 Immunostaining of KDR and CD31 in hAEC-hep cells in vitro. 
Immunostaining revealed that hAEC-hep cells were KDR positive but CD31 
negative in vitro (confocal, x60 magnification).  
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6.3.4 hAECs did not affect LX-2 cells through apoptosis in vitro 
In chapter 5.3.4, we learnt that either three types of hAEC 
transplantation resulted in a significant reduction in αSMA positive activated 
myofibroblasts. To determine if the effect of hAECs on activated 
myofibroblast was due to a paracrine effect akin to MSCs (Puglisi et al., 
2011), a co-culture experiment was set up to study their effects in vitro.  
When co-cultured with either three types of hAECs on transwell 
membranes, LX-2 showed limited apoptosis by TUNEL assay (figure 6.7). As 
a significant reduction in αSMA positive cells was seen previously, this 
observation in apoptosis implies that hAEC-mediate activated myofibroblast 




Figure 6.7 TUNEL assay of LX-2 cells with co-culture with various 
hAECs in vitro.  
TUNEL assay showed limited  apoptosis in LX-2 cells when co-cultured with 
various hAECs (epifluorescence, x40 magnification). PI refers to nuclear stain 
propidium iodide.   
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6.3.5 hAECs induced quiescence of LX-2 cells in vitro 
As there was no difference in apoptotic rate, we hypothesised that the 
activated myofibroblasts were being deactivated into a quiescent state. To 
analyse this phenomenon, we performed immunofluorescence staining of 
desmin as a surrogate marker of quiescence. LX-2 cells (activated 
myofibroblast cell line) had very little desmin labelling in their de novo state. 
However, after co-culture with either three types of hAECs, the amount of 
desmin positive cells increased dramatically, indicating quiescence (figures 
6.8-6.9). Quantification also revealed significant increases in the percentage of 
desmin positive LX-2 cells when co-cultured with either hAEC-raw, -epi or –
hep cells. 
This dramatic effect suggested that hAEC-induced quiescence of LX-2 
cells was the main mechanism of action for the decrease in αSMA positive 
activated myofibroblasts in vivo compared to apoptosis induction. However, 
no significant difference in the frequency of LX-2 quiescence was seen 





Figure 6.8 Immunostaining of LX-2 cells in co-culture with hAECs I.  
After co-culture with hAEC-raw cells, LX-2 cells showed an increase in 
desmin-positive cells, indicating that LX-2 cells were becoming quiescent 








Figure 6.9 Immunostaining of LX-2 cells in co-culture with hAECs II.  
A: After co-culture with hAEC-epi or hAEC-hep cells, LX-2 cells also 
showed increases in desmin-positive cells, indicating that LX-2 cells were also 
becoming quiescent after co-culture (epifluorescence, x40 magnification). B: 
Quantification showed significant increases in the percentage of desmin 
positive LX-2 cells when co-cultured with either hAEC-raw, -epi or –hep cells 
(*p<0.05).   
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6.3.6 hAECs increased markers of Ly6Clo macrophage activation 
and altered MMP expression 
Macrophages play an important role in fibrosis regression as they are a 
rich source of pro-fibrolytic MMPs, and also have anti-inflammatory 
properties. A recent study also showed that conditioned media of hAECs 
could directly polarize macrophages to the M2 phenotype and mediate lung 
repair (Tan et al., 2014). Macrophage therapy has also been explored as a form 
of therapy for mouse liver fibrosis (Thomas et al., 2011). With this weight of 
evidence, we were also interested in investigating the role of macrophages in 
fibrosis regression seen in our animal model.  
Manuelpillai et al. described that transplantation of hAEC-raw cells in 
vivo induced markers of M2 macrophage activation, resulting in the reduction 
of hepatic fibrosis in rodents (Manuelpillai et al., 2012). As M2 macrophages 
have been described to play a significant role in hepatic “wound healing”, 
namely fibrosis progression (Mantovani et al., 2004, Ramachandran et al., 
2012, Wynn and Barron, 2010), we found it peculiar that activation of M2 
macrophages was found to cause fibrosis regression. Hence, we sought to 
examine if this was truly the case, or was there another subset of macrophages 
in play that was causing fibrosis reversal. 
Our studies showed that hAEC-raw cells significantly increased in 
transcript levels for M1 associated gene IL-12b (3.2 folds), as well as M2 
associated gene IL-10 (4.9 folds). Their M1:M2 ratio also showed no 
significant difference after transplantation, hence it cannot be concluded in our 
study whether M2 macrophages was really the predominant macrophage 
population (figure 6.10).  
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hAEC-epi cell transplantation caused significant increases in transcript 
levels of M1 associated genes IL-12b (8.1 folds) and CCL 17 (2.2 folds), and 
M2 associated gene IL-10 (5.4 folds). hAEC-hep cell transplanation increased 
mRNA levels of M1 associated gene IL-12b (6.6 folds), and IL-10 (5.2 folds). 
For both hAEC-epi and hAEC-hep transplantation, no significant change was 
found in the other M2 associated gene, CD206, and in the M1:M2 ratio. 
Again, it was inconclusive if M2 was the predominant macrophage 
population. 
We also investigated the genes associated with the activation of Ly6Clo 
macrophages, a new macrophage subset which was recently described by 
Ramachandran et al. as anti-fibrotic, and was distinctively different from 
typical M1 and M2 macrophage populations (Ramachandran et al., 2012). 
Genes associated include CX3C chemokine receptor 1 (CX3CR1), MIF and 
CD74. Transplantation with either 3 types of hAECs resulted in significant 
increases in all three genes, suggesting that Ly6Clo macrophages were the 
predominant population of macrophages and not the M2 population. CX3CR1, 
MIF and CD74 also play important anti-inflammatory and anti-fibrotic roles, 
hence their upregulation directly correlates with the fibrosis reversal seen in 
our animals (Heinrichs et al., 2011).  
MMPs, which are produced by macrophages, play an important role in 
fibrosis regression. Here, we studied if MMP-9, a collagen degrading enzyme, 
and MMP-12, an inhibitory protein of MMP-9, changed after hAEC 
transplantation. 
mRNA expressions of MMP-9 increased significantly after 
transplantation with hAEC-epi cells (1.5 folds) and hAEC-hep cells (2.3 
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folds). Expression of its inhibitory protein, MMP-12, decreased significantly 
after transplantation with hAEC-raw cells (0.6 folds), but no change was 
detected after transplantation with the other two types of hAECs (figure 6.1).  
However, no significant changes were seen in MMP inhibitor TIMP1. 
We also studied the genetic expression of profibrotic cytokines TNFα 
and TGFβ, but no demonstrable difference was found after transplantation 






Figure 6.10 RT- PCR of genes typically associated with activated M1 and 
M2 macrophages.  
mRNA expression of M1 associated IL-12b saw significant increases after 
transplantation of either three types of hAECs, and CCL17 increased 
significantly after hAEC-epi cell transplantation. M2 associated IL-10 
increased significantly after transplantation of either three types of hAECs, but 
no change was detected in CD206. The ratio of M1:M2 macrophages (IL12b: 






Figure 6.11 RT-PCR of genes typically associated with activated Ly6Clo 
macrophages.  
mRNA expression of genes associated with activated Ly6Clo macrophages, 
CX3CR1, MIF and CD74, all saw significant increases after transplantation of 





Figure 6.12 Real time PCR of MMPs, TIMPs and pro-fibrotic cytokines.  
mRNA expression of collagen degrading MMP-9 increased significantly after 
hAEC-epi and hAEC-hep cell transplantation, and MMP-12, which inhibits 
production of MMP9, transcript levels decreased significantly after hAEC-raw 
cell transplantation. No significant change was detected in mRNA expressions 




6.4 Interpretation and conclusion 
hAECs caused significant fibrosis reduction in immuno-compromised 
mice with TA-induced chronic liver failure, and the mechanism of action of 
hAECs was explored. We ruled out that fibrosis regression was caused by the 
replacement of hepatocyte insufficiency, since we did not see a significant 
reduction in fibrosis after transplantation of adult human hepatocytes (see 
section 5.3.4). 
Oxidative stress has been associated with fibrogenesis (Poli, 2000, Poli 
and Parola, 1997), but findings from our TBARS assay revealed no significant 
change in mouse liver lipid peroxidation after transplantation with either three 
types of hAECs. Hence, it could be concluded that hAECs did not cause 
fibrosis regression through a reduction in oxidative stress. 
It has been established that the loss of fenestrations on LSECs precedes 
the onset of hepatic fibrosis. Differentiated (fenestrated) LSECs prevents the 
activation of HSCs and promotes the reversal of activated myofibroblasts to 
quiescence, therefore playing an important role in fibrosis regression (Deleve 
et al., 2008, Xie et al., 2012). Using human specific antibodies, 
immunostaining of mouse livers showed that all three types of hAECs 
differentiated into KDR and CD31 positive cells, indicative of the presence of 
LSECs. Retrospectively, we immunostained in vitro hAEC-raw, hAEC-epi 
and hAEC-hep cells, and results showed that hAEC-hep cells were positive for 
KDR but negative for CD31. Goldman et al. described this KDR+/CD31- 
population of cells as pre-hepatic cells, and this suggested that hAECs have 
the ability to become a hepatic progenitor-like state but not yet a fully 
differentiated LSEC (Goldman et al., 2013). However, under the in vivo 
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conditions of chronic liver failure, it pushed hAECs to differentiate into 
LSECs.  
To study the effect hAEC-derived LSECs had on activated 
myofibroblasts, a co-culture experiment between LX-2 cells and hAECs was 
established in vitro. Two theories were explored, namely apoptosis or 
quiescence of activated myofibroblasts. TUNEL assay showed that a small 
number of LX-2 cells underwent apoptosis after co-culture with hAECs, but 
majority of the LX-2 cells became desmin positive after co-culture. This 
suggested that the main mechanism of action of these hAEC-derived LSECs 
was through the quiescence of activated myofibroblasts, and this corroborates 
our previous data which showed a significant decrease in αSMA positive 
activated myofibroblasts after hAEC transplantation.  
Lastly, we studied which macrophage population was predominantly 
active during fibrosis regression, and whether MMPs, TIMPs and profibrotic 
cytokine profiles were altered after transplantation. mRNA expression profiles 
revealed that the main active macrophage population after hAEC 
transplantation was Ly6Clo population and not M2 population which was 
previously described by Manuelpillai et al. (Manuelpillai et al., 2012). Tan et 
al. (Tan et al., 2014) also showed the causal link between hAECs and 
macrophage polarisation, suggesting that this hAECs could also be causing the 
same effect on macrophages in vivo.  
 
Table 10 Properties of various macrophage phenotypes 





MMP-9 plays a pivitol role in collagen degradation; its expression was 
increased significantly after transplantation with hAEC-epi and hAEC-hep 
cells, and. hAEC-raw cell transplantation did not see a significant increase in 
MMP-9 mRNA levels; instead resulted in a significant down regulation in 
MMP-9’s inhibitory molecule, MMP-12. Although transplantation with 
hAEC-raw or hAEC-epi/hep cells exerted different effects on MMPs, the end 
result of fibrosis regression was similar. hAEC transplantation, however, did 
not cause any significant change in TIMP-1 levels, or profibrotic cytokines 
TNFα and TGFβ. 
Between the three different types of hAECs transplanted, we did not 
see a significant difference in the mechanism of action for fibrosis regression. 
Even after in vitro culture and differentiation, hAEC-epi and hAEC-hep cells 
still retained the ability to regress fibrosis.  
Therefore, we conclude that hAECs have the ability to reverse fibrosis 
through several complimentary pathways (figure 6.13). Firstly, spontaneous 
differentiation into LSEC in vivo, and this probably caused the quiescence of 
activated myofibroblasts, hence attenuating further ECM deposition caused by 
these cells. Also, hAECs up regulated the Ly6Clo macrophage population, 
which not only up regulated the genetic expression of anti-inflammatory and 
anti-fibrotic cytokines, but also increased MMPs. Taken together, there 




Figure 6.13 Schematic diagram of hAEC mediated fibrosis regression 
 
6.5 Limitations 
In order to directly prove the presence of fenestrations on hAEC-
derived LSECs, scanning electron microscopy (SEM) was performed using 
human-specific immunogold labelling for specificity. However, due to 
technical difficulties and the lack of proper fixation of tissue samples in 
gluteraldehyde during time of tissue collection, we were unable to pursue 




Chapter 7 In vivo paracrine effect of hAECs in immuno-
competent mice 
7.1 Introduction 
In previous chapters, we have seen that hAECs successfully engrafted 
into parenchyma of mice and improved the state of fibrosis and chronic liver 
failure, both structurally and functionally. hAECs produce anti-inflammatory 
molecules such as MIF and soluble HLA-G, and in chapter 6, we saw that 
hAECs exerted a paracrine effect on LX-2 cells, reverting them to their 
quiescent state.  
To determine if hAECs would also have a paracrine anti-inflammatory 
effect in an acute injury models, we transplanted hAEC-epi cells and their 
conditioned media (CM) into C57BL/6 mice with acute liver failure. As acute 
liver failure occurs with widespread hepatocellular necrosis and inflammation, 
immuno-competent mice were selected to recapitulate the disease physiology, 
which requires intact immunity.  
We aimed to study if these hAECs/ CM, when transplanted intra-




7.2 Materials and methods 
7.2.1 Animals 
The immuno-competent strain of C57BL/6 mice were used in this part 
of the study. Please refer to section 5.2.1 for more details on animal 
husbandary.  
 
7.2.2 Induction of acute liver failure 
Acute liver failure was induced using anti-Fas antibody, Jo-2 (Sigma 
aldrich), according to previously published protocols (Gandillet et al., 2005, 
Vidal et al., 2008). 200µg/kg of Jo-2 antibody was dissolved in PBS, and one 
dose was injected intra-peritoneally into each C57BL/6 mice. 
 
7.2.3 Xenotransplantation into animals with acute liver failure 
We were limited by the ability to intrasplenically transplant cells into 
these animals as they were very sick and would not survive the surgery. We 
hypothesised that the hAEC anti-inflammatory effect was via cytokines, 
microsomes or exosomes rather than actual cellular effect in the liver. Thus we 
tested if this paracrine effect was sufficient in salvaging acute liver injury. 
Three exprimental arms were used in this part of the study, namely: 
1. PBS sham-injection 
2. hAEC-epi cells 
3. Conditioned media from cultured hAEC-epi cells 
As our purpose was to investigate if hAECs had any paracrine anti-
inflammatory effect, we chose to transplant through the intra-peritoneal route 
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instead of intra-splenically. Conditioned media was obtained from in vitro 
culture of hAEC-epi cells. 200µl of PBS or conditioned media was injected, 
and two million cells in 200µl of PBS was transplanted into respective 
animals.  
hAEC-epi cells or media were transplanted into animals 4 hours post 
induction of acute liver failure by Jo-2. Animals were then sacrificed 24 hours 
post Jo-2 administration at the peak of hepatic inflammation. Ten animals 
were used in each experimental arm. 
 
7.2.4 Mouse serum analysis 
Please refer to section 5.2.6 for more details. 
 
7.2.5 Statistical analysis 
Please refer to section 4.2.11 for more details.  
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7.3 Results  
7.3.1 hAEC-epi cells and CM showed no statistical significant 
paracrine anti-inflammatory effects in mice 
Jo-2 is an anti-Fas ligand, and the introduction of Jo-2 into animals 
would cause the stimulation of the Fas apoptotic pathway, resulting in 
widespread liver inflammation and acute failure (Gandillet et al., 2005, 
Ogasawara et al., 1993). 
After Jo-2 infusion, our animals did develop acute liver failure with 
serum ALT, AST and total bilirubin levels spiking to a mean of 12926U/L, 
16132U/L and 1.4mg/dL respectively (figure 7.1). These levels were all 
beyond the normal reference range.  
After transplantation of hAEC-epi cells or their conditioned media 
intra-peritoneally into three animals each, we examined the serum ALT, AST 
and total bilirubin levels to investigate if inflammation had reduced. However, 
no significant change was detected in transplanted animals compared to their 
PBS controls (figure 7.1). 
We then moved on to increase the power of the study by increasing the 
number of animals used, but even at n=10 for each experimental arm, no 
statistical significance was detected. Hence, we do not have enough evidence 






Figure 7.1 Mouse serum markers of acute liver injury.  
After intra-peritoneal transplantation of hAEC-epi cells or their conditioned 
media, no significant improvements were seen in serum ALT, AST and total 
bilirubin levels.  
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7.4 Interpretation and conclusion 
In this chapter, we attempted to further investigate if there was a 
paracrine anti-inflammatory effect of hAECs in acute liver failure, as this can 
potentially have great impact in medical therapeutics as soluble molecules can 
be developed into drugs for treatment of diseases.  
After intra-peritoneal injections of hAEC-epi cells and their 
conditioned media, a trend of reduction was seen in serum markers of liver 
injury such as ALT, AST and total bilirubin. However, the findings did not 
achieve statistical significance even after increasing the study cohort to 10 
animals. Hence, we do not have enough evidence to conclude if hAEC-epi 




One major problem we faced was the high variability between animals. 
As Jo-2 is an anti-Fas ligand that causes widespread apoptosis and necrosis, 
individual immunity of animals may affect the extent of injury and by 
extension, the extent of salvage (Matsumura et al., 2000, Modiano et al., 
2012). Also, the avalanche of inflammation caused may be too great for the 
paracrine effect of hAECs to reverse, and this highlights the difficulty and 
complexity of acute liver failure treatment seen in the clinical setting 
(McDowell Torres et al., 2010).  
A single dose of conditioned media may also have been insufficient 
and have too short a half life to make a significant difference. It would have 
been ideal if we could transplant cells into the animals to see if there was any 
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thereapeutic effect, but the animals were too unwell with extremely high 
mortality to make this possible. It is envisaged that a continuous pump of CM 
over a period of time may be able to test the anti-inflammatory effect of 
hAECs better. That being said, earlier data has shown in chapter 5 showed that 
the anti-inflammatory effect of hAECs in the cirrhosis model, even with 
cellular transplantation, showed modest and insignificant reductions in serum 
ALS and AST levels. Hence, the dilemma of what to transplant (cells or CM) 
remains, and requires more investigation.   
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Chapter 8 Discussion 
8.1 hAECs, the cells with an unique advantage 
The potential of stem cell therapy for liver failure has been a field of 
intense research. While many cell candidates including mesenchymal stem 
cells (Lee et al., 2004) and induced pluripotent stem cells (Si-Tayeb et al., 
2010) have been shown to be capable of converting into hepatocytes, hAECs 
remain a highly attractive candidates. The placenta plays the role of a barrier 
that protects the fetus from maternal immunity, and is also fetal and retains 
plasticity that allows for in vitro manipulation. Inspired by nature, we adopted 
this unique cell type and applied it to the treatment of chronic liver diseases.  
Unlike many stem cell candidates limited by cell numbers, the placenta 
is usually discarded after childbirth, providing a limitless supply of cells. 
hAECs also do not carry with it the ethical concerns that fetal liver or 
embryonic stem cells do. 90% of patients approached to participate in this 
study were willing to donate their placentas for research, and this suggested 
that a steady supply of hAECs would not be an issue in future scale-up work.  
The human amniotic membrane was easy to dissociate in vitro, 
yielding 20-50 million hAECs per placenta. These cells were also able to 
tolerate freeze-thaw very well, and freezing them down using 10% dimethyl 
sulfoxide (DMSO) yielded a revival rate of at least 50%. This is also an 
important feature for future scaling up work.  
Being fetal in origin, these cells are highly plastic and have been 
reported to improve hepatic and lung fibrosis in rodents (Hodges et al., 2012, 
Manuelpillai et al., 2012). Immunophenotyping showed that hAEC-raw cells 
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were pluripotent and bore epithelial markers, typical of primitive cells 
(Carnevale et al., 2013, Li et al., 2011). They were also positive for the 
important immuno-modulatlory molecule, HLA-G, as described in chapter 
2.3.3. hAEC-raw cells also presented with glycogen storage, and when 
differentiated into hAEC-hep cells, they still retained this funtional ability 
(results not shown).  
Taken together, hAECs have a unique advantage over other sources of 
stem-cell derived hepatocytes because of their immuno-modulatory 
characteristics, abundance in cells numbers and lack of ethical hurdles. hAECs 
are less likely to be rejected by host immunity and are readily avaliable in 
large numbers for transplant. Our analysis, together with evidence in the 
literature of the hepatic potential of hAECs, suggest that hAECs are an 
excellent cell source for potential cellular therapy in patients with liver failure.  
 
Table 11 Comparison of beneficial characteristics between hAECs and 
various stem cells. Adapted from Broughton et al. (Broughton et al., 
2012). 
Benefits hAECs ESCs MSCs iPSCs 
Fetal 
liver 
Readily available ✓ ✗ ✓ ✓ ✗ 
Available in large quantities ✓ ✗ ✓ ✓ ✗ 
Pluripotent properties ✓ ✓ ✗ ✓ ✓ 
Non-immunogenic ✓ ✗ ✗ ✗ ✗ 
Non-tumorigenic ✓ ✗ ✗ ✗ ✓ 
Differentiate into hepatic cells ✓ ✓ ✗ ✓ ✓ 
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8.2 Hepatic differentiation potential of hAECs in vitro 
Our data confirmed that hAECs were capable of differentiating into 
hepatocyte-like cells in vitro, with hepatocyte-specific functions. Using a four 
stage differentiation protocol derived from iPSC culture, we exposed hAECs 
sequentially to hepatic growth factors and bile salts to simulate natural 
signaling of a developing fetal liver. This method was free of animal feeder 
layers or serum, and the duration was only 18 days.  
Differentiated hAEC-hep cells showed cellular morphology that was 
hepatocyte-like, proliferated densely throughout the 18 days and developed 
bile canaliculi, a definitive characteristic of mature hepatocytes. They lost 
stem cell gene profile as seen in the significant down regulation of Oct-4, 
NODAL, EPCAM, CD44 and BMP4. Instead, hAEC-hep cells switched to an 
increased expression of genes involved in liver functions, CYP450 genes and 
hepatocyte specific transcription factors. Immunophenotype analysis also 
revealed that hAEC-hep cells displayed hepatic specific cell surface markers 
such as HNF-4, α1AT, AFP and albumin, and retained their HLA-G 
immuophenotype. hAEC-hep cells also demonstrated qualitatively the 
functional capabilities of liver cells such as albumin secretion, inducible 
CYP450 enzymatic activites, ICG uptake and clearance, and LDL uptake. 
We also cultured and maintained hAEC-epi cells for 18 days, the same 
duration as hAEC-hep cells undergoing differentiation, as a form of parallel 
control. We were interested in investigating if hAEC-epi cells would display 
some hepatocytic characteristics, since Takashima et al described hAECs to 
possess hepatocyte-like characteristics in the de novo state (Takashima et al., 
2004). Indeed, hAEC-epi cells displayed some hepatocytic characteristics, 
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such as up regulation in genes invovled in liver functions, CYP450 genes and 
hepatocyte specific transcription factors. However, the list of genes 
upregulated was not as extensive as that displayed by hAEC-hep cells. hAEC-
epi cells also lost their stem cell gene profile, suggesting that hAECs will start 
to differentiate from their fetal state when cultured for extended periods in 
vitro. However, these cells did not show any hepatic functional abilities as 
hAEC-hep cells did, giving evidence that our differentiation protocol was 
effective and crucial in generating functional hepatocyte-like cells.  
In our study, we characterised and demonstrated the functional abilities 
of hAEC-hep cells, an area yet to be described extensively in literature. 
Comparatively, our differentiation protocol achieves functional hepatocyte-
like cells in the shortest amount of time and also demonstrated convincing 
liver genetic and functional profiles more than other studies published 
(Ilancheran et al., 2007, Luo et al., 2011, Miki et al., 2005, Takashima et al., 
2004, Vaghjiani et al., 2013). 
 
8.3 hAECs improved chronic liver injury in NSG mice 
NSG mice were chosen as the strain used in this study because of their 
immunopermissive background and their high engraftment rates in stem cell 
studies (Akkina, 2013, Amabile et al., 2013, Lahar et al., 2011, Shultz et al., 
2007, Shultz et al., 2005). We believed that this strategy would give hAECs 
the best chance of survival and engraftment in the mouse, thereby allowing us 
to study its in vivo efficacy.  
One month after transplantation of either hAEC-raw, hAEC-epi and 
hAEC-hep cells into NSG mice with chronic liver failure, there was a 
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significant reduction in the number of visible nodules was seen, where the 
livers appeared to be less shrunken compared to control animal livers. 
Immunofluorescence staining also revealed the presence of human-specific 
HLA-G and albumin surface markers indicating that all three types of 
transplanted hAECs had engrafted, survived in vivo, retained its ability to 
escape immune surveillance and were functioning as a hepatocyte-like cells. 
hAEC-raw cells also differentiated into albumin-positive cells in vivo. 
hAEC-hep cell transplantation significantly improved clinical 
correlates of chronic liver failure, such as mouse serum albumin and total 
bilirubin levels, whereas hAEC-epi cells only improved albumin, and hAEC-
raw cells exerted no significant improvement in these serum markers. 
However, the improved serum albumin and bilirubin levels were still 
significantly lower than animals transplanted with human adult hepatocytes. 
PT also improved significantly after transplantation with either three types of 
hAECs, and hAEC-epi cells were able to evade host immunity of C57BL/6 
mice and engraft successfully in the mouse livers. 
Taken together, hAEC-hep cells showed best in vivo efficacy after 
transplantation compared to hAEC-raw and hAEC-epi cells. This 
demonstration of principle of proof provided the most direct evidence that 
these cells may be useful for clinical therapy.  
 
8.4 hAECs caused fibrosis regression in rodents 
Transplantation of all three types of hAECs into NSG mice with 
chronic liver failure showed in vivo efficacy in reversal of fibrosis. Significant 
reductions in fibrosis-causing collagen fibres was seen with a concomitant 
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decrease in activated myofibroblasts. Surprisingly, transplantation of human 
adult hepatocytes did not improve fibrosis or decrease the number of activated 
myofibroblasts. In this aspect, transplantation of hAECs was superior to 
human adult hepatocytes. 
Investigation into the mechanism of action hAECs had on fibrosis 
regression showed that it was caused by 1) in vivo differentiation of hAECs 
into LSECs, 2) activation of antifibrotic Ly6Clo macrophage population and 3) 
modulation of MMP expression. The presence of LSECs could have plausibly 
normalised its cross-talk with activated myofibroblasts, and our in vitro data 
suggested that hAECs promoted the quiescence of LX-2 cells. Contrary to 
evidence presented by Manuelpillai et al(Manuelpillai et al., 2012), M2 
macrophages were not the predominantly active population induced after 
hAEC transplantation, but it was the Ly6Clo population. This population 
increased CX3CR1 gene which is involved in anti-inflammatory macrophage 
programme, and also increased antifibrotic genes MIF and CD74. It also 
increased collagen-degrading MMP-9 expression in animals transplanted with 
hAEC-epi and hAEC-hep cells, and decreased the expression of MMP-12, the 
inhibitory molecule of MMP-9, after hAEC-raw transplantation. 
 
8.5 hAECs, LSEC and Ly6Clo macrophages. Are they related? 
Our results have shown that hAECs can cause the quiescence of 
activated myofibroblast cell line, LX-2. This then begs the question of whether 
there was a direct causal effect, or was it mediated through differentiation into 
LSECs, which have the ability to cause quiescence in activated 
myofibroblasts. In vitro, we did not find CD31 positivity in cultured hAECs, 
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but we found that they spontaneously differentiated into CD31+ LSECs in 
vivo.  
The role of LSECs may also be more than what has been perceived. 
They are the basal cells in contact with hepatocytes, regulate oxygenation and 
nutrition to liver cells via fenestrations, and have a role in immuno-regulation 
(Braet and Wisse, 2002, De Leeuw et al., 1990). They could also have anti-
fibrotic capabilities, but are damaged as the first step of fibrosis (Deleve et al., 
2008).  
In literature, it has been shown that LSECs represent a special type of 
scavanger cell that has the ability to eliminate macromolecules through 
receptor-mediated pinocytosis (Seternes et al., 2002, Smedsrod, 2004). The 
common thread between LSECs and macrophages here lies in the fact that 
both population of cells possess scavaging activities. Whether or not the 
hAEC-derived LSECs and Ly6Clo cell population are the same cells, or 
whether they have developmental influence on each other remains unknown. It 
is possible that they are independent processes and a subject of future pursuit.  
HLA-G has been described to confer immunosuppression by 
suppressing NK cells and inhibiting CD4+ T cell proliferation (Dorling et al., 
2000). These helper T cells influence the equilibrium between pro-fibrotic and 
pro-resolution macrophage populations (Pellicoro et al., 2014) and could 
possibly explain why HLA-G caused Ly6Clo activation.  
The direct link between hAECs, LSECs and macrophages remains 




8.6 Are hAECs a good potential cell candidate for patient 
therapy?  
We have presented extensive evaluation of in vitro and in vivo 
capabilities of hAECs in becoming functional hepatocyte-like cells and also 
their ability to mitigate chronic liver failure in rodents and improve clinical 
correlates of cirrhosis. Their benefits were multi-factorial, namely: 
1. hAECs differentiated spontaneously into LSECs in vivo, 
inducing the quiescence of activated myofibroblasts with a 
resultant reduction in fibrosis. 
2. hAECs possess immuno-modulatory properties and activated 
Ly6Clo anti-fibrotic macrophage population. 
3. hAEC tranplantation altered the expression of MMPs genes 
that favoured fibrolysis of ECM. 
We believe that all three factors were equally important in the 
improvement of a cirrhotic liver. A summary of the key findings in this thesis 
is shown in Table 9. 
Across all three types of hAECs studied, hAEC-hep cells showed the 
“best” hepatocyte function and characteristics in vitro. Their differences 
became less distinct when transplanted into animals, as spontaneous hepatic 
differentiation was observed even in hAEC-raw cells. All three hAEC cell 
types could reduce fibrosis significantly via similar mechanisms. However, 
transplantation with hAEC-hep cells showed a marked improvement in 
synthetic and excretory liver functions, which were lacking in hAEC-raw and 
hAEC-epi cell transplantations. In this respect, hAEC-hep cells had superior in 
vivo functions compared to the other two hAEC cell types.  
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Therefore, we believe that hAECs are a good cell source for patient 
therapy and that hAEC-hep cells are the best cell candidates.; they did not lose 
their immuno-modulatory function even post in vitro differentiation and 
exerted the most convincing in vivo effects. Nonetheless, further evaluation on 
their safety profile and long term studies in animals need to be performed for 




Table 12 Summary of capabilities of hAEC-raw, hAEC-epi and hAEC-epi 
cells, both in vitro and in vivo. 






Hepatic structure and 
morphology 





Hepatic phenotype + ++ +++ 
Hepatic function + + +++ 
HLA-G + + + 
Quiescence of LX-2 ++ ++ ++ 
In vivo 
Improvement of mouse liver 
macro-morphology 
+++ +++ +++ 
Engraftment,  
Alb+/ HLA-G+ 
+++ +++ +++ 
Fibrosis reduction +++ ++ +++ 





Liver excretory function  






Liver coagulopathy  
(prothrombin time) 
+++ +++ +++ 
hAEC differentiation into 
LSEC 
++ ++ ++ 
Ly6Clo macrophage 
activation 












8.7 Scientific and clinical significance  
In this study, we compared hAECs at different points of hepatic 
differentiation both in vitro and in vivo. We also established an in vitro 
differentiation protocol that was free from animal additives, efficient and 
reproducible. This is an important aspect for future scale up work that requires 
cells to be GMP grade.  
We described comprehensively the benefits of hAEC transplantation in 
terms of clinical correlates; the data we have garnered are valuable and 
relevant especially in the clinical setting. We also assessed and compared the 
anti-fibrotic effect of these cells in vivo, and elucidated their mechanism of 
action. Although there were no significant difference found between the cell 
types, this study remains to be the first extensive description of the anti-
fibrotic capabilities for hAECs.  
This is both scientifically and clinically significant as this model could 
be used to study fibrosis regression and their highly co-ordinated regulatory 
pathways involved, which in turn would have clinical implications. This 
therapeutic effect also holds great promise for the treatment of fibrosis in other 
organs and may drive a multi-organ approach in the study of fibrosis.  
 One major challenge in the translational process from bench to 
bedside is the safety profile of the cell of interest. Stem cells are known for 
their ability to genetically transform, and there remains an underlying fear that 
these cells may become oncogenic once transplanted into patients. Although 
the safety profile of differentiated hAECs needs to be further investigated, 
hAECs have been shown to not express telomerase (Miki et al., 2005) and 
hence the risk of genetic transformation would be lower. Cytogenetic studies 
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should also be performed to assess the chromosomal stability of in vitro 
differentied hAECs.  
Another challenge would be the need for patients to undergo long term 
immuno suppression to prevent rejection of transplanted cells. We have shown 
that hAECs engrafted into the liver of immunocompetent C57BL/6 mice, and 
this property gives it its unique advantage over other stem cells in terms of 
“evasion” of host immunity. This would reduce the need to be on long term 
immunosuppressive drugs, in turn saving costs for the patient and reducing the 
risks of contracting opportunistic infections. 
 
8.8 Recommendations for clinical cellular therapy 
Our data showed that albumin positive hepatocyte-like cells could be 
found in mouse liver regardless of prior hepatic differentiation, suggesting that 
the in vivo liver injury environment was sufficient to spontaneously 
differentiate hAECs into hepatocytes. This has implication in stem cell 
applications when balancing between urgency for functional hepatocytes for 
transplantation and avoiding ex vivo manipulation for safety considerations. 
As such, each hAEC cell type explored in this study has its advantages, 
and could even be used in combination to achieve targeted results. 
hAEC-raw cells were able to spontaneously differentiate into 
hepatocyte-like cells in vivo, retained its ability to evade host immunity, and 
showed good anti-fibrotic effects. hAEC-epi cells had all of the above-
mentioned characteristics, and showed changes in serum total bilirubin levels. 
hAEC-hep cells also had all the mentioned characteristics, and demonstrated 
striking improvements in serum albumin and total bilirubin levels.  
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Hence, for the purpose of fibrosis regression, hAEC-raw cells would 
be the best candidate for cellular therapy as this eliminates the need for ex vivo 
manipulation of hAECs, thereby reducing safety-related considerations. 
However, if there is a need to replace hepatocyte insufficiency, hAEC-hep 
cells would be a better candidate for transplantation since it had the best 
hepatocyte-like functions. hAEC-raw cells may also have some protective 
effect when transplanted in combination with other cell types such as MSCs or 
iPSCs, but this remains to be investigated futher. 
 
8.9 Future directions 
Even though hAECs have displayed great potential in this study, work 
remains to be done to eventually translate this into the clinical applications to 
treat patients. These include:  
1. Developing good medical practice (GMP) protocols to avoid 
contaimnation of hAECs with animal peptides. Cytogenetic 
testing on hAEC derived cells also needs to be done to screen 
for oncongenic potential. 
2. Explore methods to cryopreserve hAECs with high cell 
viability for use when needed. It was projected that at least 200 
million cells will be required to exert a sizeable functional 
benefit to a normal sized adult(Hughes et al., 2012). In order to 
pool together enough cells to achieve such numbers, the ability 
to cryopreserve or even vitrify hAECs would be crucial. 
3. Examine the soluble factors released by hAECs using mass 
spectrometry analysis. This would help to elucidate the active 
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ingredients that could have a paracrine anti-inflammatory 
effect, and could be developed into an exosomal vesicle for 
therapeutic purposes. 
4. Analyse the long-term in vivo efficacy of hAECs. This would 
ascertain how long hAECs can survive in a foreign host, and 
also need be, when to administer a new dose of hAEC 
transplantation. Repeated doses of hAECs can also be studied 
to investigate if it will increase their in vivo efficacy. 
5. Transplantation of hAEC-hep cells into immunocompetent 
C57BL/6 mice with chronic liver injury to study their in vivo 
efficacy and also their ability to evade host immunity. After 
which, studies also need to be done in larger animal models 
such as pigs. 
6. Improving the in vitro differentiation protocol to improve 
CYP450 genetic profile, and also decrease duration of protocol 
if possible. As pharmaceutical companies need large amounts 
of hepatocytes for drug testing, a good CYP450 gene profile 
would be pivotal. Therefore, if the current CYP450 gene profile 
of hAEC-hep cells can be improved, hAECs would have an 
additional application in the pharmaceutical industry. 
7. FACS studies to examine the purity of hAEC-raw cells, and 
also the quality of in vivo differentiated hAECs. 
8.  In depth analysis of the interactions between hAEC, LSEC and 




In this study, we used a method of hepatic differentiation on hAECs 
that was both effective and efficient, and charaterised in vitro hAEC-hep cells 
extensively.  
We demonstrated that hAECs were able to differentiate into functional 
hepatocyte-like cells in vitro, up regulating liver-specific genes, exhibiting 
liver cell surface markers, and also acquiring many liver-specific functions.  
Most significantly, hAECs were able to demonstrate prood of principle 
that they could induce reversal of fibrosis, augmentation of liver function and 
improve clinical functional correlates of liver failure in chronic liver injury 
model. This was achieved through 2 main effects – augmentation of hepatic 
function by hepatocyte differentiation as well as a non-parenchymal effect of 
fibrosis reversal, the latter being achieved by LSEC replacement leading to  
quiescence of activated myofibroblasts, macrophage phenotypic switch to 
Ly6Clo anti-fibrotic phenotype and alterations to MMP expression in favour of 
fibrolysis. This comprehensive dual effect, in addition to its ability to escape 
immune rejection, makes hAECs a potentially useful tool for clinical therapy. 
With its immunomodulatory characteristics, ability to differentiate into 
functional hepatocyte-like cells, and the advantage of limitless supply, hAECs 
are potentially useful for cell therapy in the aim of improving outcomes for 
patients with cirrhosis.  
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